

# INDEX

Volume Thirty-two — January through December 1998

## The Annals of Pharmacotherapy

JANUARY Pages 1–156; S1–30  
FEBRUARY Pages 157–280  
MARCH Pages 281–398  
APRIL Pages 399–518

MAY Pages 519–626  
JUNE Pages 627–732  
JULY/AUGUST Pages 733–862  
SEPTEMBER Pages 863–1000

OCTOBER Pages 1001–1130  
NOVEMBER Pages 1131–1268  
DECEMBER Pages 1269–1402

## SUBJECT INDEX

### A

**$\alpha$ -Adrenergic blockers**, see **Sympatholytic agents**  
**Abciximab**, cost-effectiveness (RR) 536; correction to figure (L) 845  
**Absorption**, gabapentin, effect of food (RR) 405; tacrolimus, continuous vs. interrupted enteral feeding (RR) 633  
**Acquired immunodeficiency syndrome**, cytomegalovirus disease, cidofovir (A) 1181; trimethoprim/sulfamethoxazole, tremor (CR) 189; wasting syndrome, recombinant human growth hormone (A) 437, review (A) 446  
**Acyclovir**, neurotoxicity (A) 111  
**Adverse reactions**, aldesleukin, management (A) 1346  
**Advertising**, drug, India (A) 1234  
**AIDS**, see **Acquired immunodeficiency syndrome**  
**Albendazole**, thrombocytopenia (L) 842  
**Alderman, Christopher P.**, board-certified Psychiatric Pharmacist (NC) 398; chairman, Committee of Specialty Practice in Psychiatric Pharmacy, Society of Hospital Pharmacists of Australia (NC) 861  
**Aldesleukin**, toxicity management (A) 1346  
**Alteplase**, compared with anistreplase, reteplase, streptokinase, myocardial infarction (A) 769  
**Ambulatory care**, compliance, elderly (RR) 749; coronary artery disease, insulin (A) 233; diabetes mellitus, type 2, management by pharmacists (RR) 636; drug information, elderly (RR) 743; interpersonal skills, community pharmacists (RR) 409  
**Aminoglycosides**, Hartford nomogram (RR) 417; once-daily administration (L) 1109  
**Amiodarone**, granuloma (CR) 60  
**Amlodipine**, compared with mifepradil (A) 664; neuromuscular complications (CR) 1165  
**Amphotericin B**, test dose (A) 475  
**Ampicillin**, neurotoxicity, premature neonates (A) 482  
**Analgesics**, prescription and nonprescription, Sweden (A) 485  
**Angaran, David M.**, Managed Care Practitioner in Residence, ASHP (NC) 518  
**Angina**, mifepradil (A) 665; unstable, low-molecular-weight heparins (A) 103  
**Angiotensin II blockers**, compared with ACE inhibitors, cough and angioedema (A) 1060  
**Angiotensin-converting enzyme inhibitors**, compared with angiotensin II blockers, cough and angioedema (A) 1060; endothelial dysfunction (A) 460; end-stage renal disease, children (A) 933; losartan as alternative (A) 1096; prior therapy, effect on MI (RR) 1141  
**Anistreplase**, compared with alteplase, reteplase, streptokinase, myocardial infarction (A) 769  
**Antacids**, bezoars (A) 942; interactions, azole antifungals (A) 923  
**Antibiotics**, fever, neutropenia management, chemotherapy (A) 1317; resistance (A) 1231  
**Antidiabetic agents**, interaction, azole antifungals (A) 923  
**Antiepileptic drugs**, cost (E) 1242; interactions, review (A) 554; pregnancy (A) 794, 802; treatment challenges (E) 1239  
**Antifungal drugs**, azole, drug interactions (A) 915; *Candida* spp. (A) 1353  
**Antihistamines**, non-sedating, interaction, azole antifungals (A) 915

**Antiinflammatory drugs, nonsteroidal**, hepatitis (VO) 386  
**Antiretrovirals**, interaction, azole antifungals (A) 920  
**Appetite suppressants**, obesity (A) 88  
**Aspirin**, burn of oral cavity (VO) 1107; enteric-coated, bezoars (A) 943; with heparin, death of pregnant woman (NC) 860  
**Asthma**, Medicaid compared with disease-based DUR (RR) 1290  
**Atorvastatin**, adverse reactions (A) 1037; compared with colestipol (A) 1033; compared with lovastatin (A) 1034; compared with niacin (A) 1034; compared with pravastatin (A) 1036; compared with simvastatin (A) 1036; cost (A) 1039; interactions (A) 1038; pharmacokinetics (A) 1032; pharmacology (A) 1032  
**Atovaquone**, with enteral nutrition, bioavailability (RR) 1004  
**Atrial fibrillation**, with factor VII deficiency, anticoagulation (L) 1251  
**Azathioprine**, hypersensitivity (CR) 425  
**Azithromycin**, compared with clarithromycin and erythromycin (A) 785; drug interactions, review (A) 790; interaction, warfarin (L) 369; pharmacokinetics (A) 787

### B

**$\beta$ -Blockers**, see **Sympatholytic agents**  
 **$\beta$ -Lactam/ $\beta$ -lactamase inhibitors**, community-acquired pneumonia (A) 522  
**Behavior**, health, impact on pharmacotherapy (A) 1076  
**Benazaprine**, interaction, azole antifungals (A) 920; pregnancy (A) 809  
**Bezoars**, medication, review (A) 940  
**Bicarbonate**, end-stage renal disease, children (A) 936  
**Bioavailability**, atovaquone, with enteral nutrition (RR) 1004  
**Bismuth salts**, interaction, tetracycline (L) 387  
**Book reviews**, A Dictionary of Natural Products (GM Hocking) 509; Antiarrhythmic Drugs: A Practical Guide (RN Fogoros) 137; Basic & Clinical Pharmacology, 7th Edition (BG Katzung) 508; Combination Drug Therapy for Hypertension (LH Opie, FH Messerli) 986; Drug Action in the Central Nervous System (PM Carvey) 1374; Dubois' Lupus Erythematosus, 5th Edition (DJ Wallace, BH Hahn) 137; Epilepsy: 199 Answers (A Doctor Responds to His Patients' Questions) (AN Wilner) 1255; Handbook of Analytical Therapeutic Drug Monitoring and Toxicology (SHY Wong, I Sunshine) 272; Health Care Fraud: Criminal, Civil and Administrative Law (PH Bucy) 987; Lyme Disease (DW Rahn, J Evans) 1256; Measurement of Pain in Infants and Children (GA Finley, PJ McGrath) 1115; Pediatric Medication Education Text (ML Buck, AE Hendrick) 721; Pharmacogenetics (WW Weber) 986; Pharmacotherapy Handbook (BG Wells, JT DiPiro, TL Schwinghammer, CW Hamill) 721; Pharmacy and the US Health Care System, 2nd Edition (JE Fincham, AJ Wertheimer) 1255; Principles and Practice of Pharmacology for Anaesthetists, 3rd Edition (TN Calvey, NE Williams) 271; Sacred Space: Stories from a Life in Medicine (C Cleaveland) 1374; Spilker's Guide to Clinical Trials on CD-ROM (B Spilker) 508; Teaching and Learning Strategies in Pharmacy Ethics, 2nd Edition (AM Haddad) 846; The Integration of Pharmacological and Nonpharmacological Treatments in Drug/Alcohol Addictions (NS Miller, B Stimmel), 1115; Your Child and Epilepsy (RJ Gumm) 1116  
**Books received**, 138, 272, 722, 846, 1116, 1256, 1375  
**Bootman, J Lyle**, chairman, Pharmaceutical Care Management

Association's Deans Advisory Council (NC) 626; George F Archambault Award (NC) 280; Outstanding Achievement Award, University of Minnesota (NC) 1392; president-elect, American Pharmaceutical Association (NC) 155  
**Botulinum toxin type A injection**, frown lines (A) 1365  
**Bupivacaine**, respiratory depression (CR) 653  
**Bupropion**, smoking cessation (A) 1362

### C

**Calcitriol**, end-stage renal disease, children (A) 936  
**Calcium**, corticosteroid-induced osteoporosis (A) 970  
**Calcium-channel antagonists**, end-stage renal disease, children (A) 933; interaction, azole antifungals (A) 920; mifepradil, review (A) 659  
**Canada**, abciximab, cost-effectiveness (RR) 536  
**Cancer**, colorectal, irinotecan (A) 1324; fever and neutropenia management (A) 1317; topotecan (A) 1334  
**Candida** spp., epidemiology (A) 1353  
**Carbamazepine**, concentration, viral hepatitis (L) 1369; drug interactions, review (A) 557; pregnancy (A) 808; rash, blood dyscrasias (CR) 884  
**Carbidopa/levodopa**, cost, Sinemet CR compared with standard Sinemet (RR) 878  
**Cardiology**, ACE inhibitors compared with angiotensin II blockers, cough, angioedema (A) 1060; ACE inhibitors effect of prior therapy on MI (RR) 1141; counseling, cardiovascular disease (NC) 517; endothelial dysfunction, marker for cardiovascular disease (A) 459  
**Carvedilol**, heart failure (A) 376  
**Catheters**, dual-lumen, delivery of incompatible medications (RR) 875  
**CD-ROM review**, pharmacotherapy.complete/WIN/MAC compatible CD-ROM, 846  
**CDs Received**, 847  
**Chemotherapy**, fever and neutropenia management (A) 1317  
**Chlamydia pneumoniae**, atherosclerosis (A) 1310  
**Chloroguanide**, hepatitis (CR) 1023  
**Cholestyramine**, bezoars (A) 942  
**Chromium picolinate**, overdose (CR) 428  
**Cidofovir**, adverse reactions (A) 1187; cost (A) 1188; cytomegalovirus disease (A) 1181; dosage (A) 1188; herpesvirus (A) 1184; intravitreal, cytomegalovirus retinitis (A) 251; pharmacokinetics (A) 1183  
**Cimetidine**, stress ulcer prophylaxis (RR) 869  
**Ciprofloxacin**, interaction, phenytoin (L) 1110  
**Cisapride**, interaction, azole antifungals (A) 916; syncope, QT prolongation (CR) 648  
**Clarithromycin**, leukocytoclastic vasculitis (CR) 543  
**Clindamycin phosphate**, *Clostridium difficile* toxin colitis (CR) 309  
**Clinical studies**, atorvastatin (A) 1033; carvedilol (A) 376; cidofovir (A) 1185; corticosteroids (A) 224; dalteparin (A) 591; donepezil (A) 71; enoxaparin (A) 593; evidence-based pharmacotherapy (A) 1193; fosfomycin tromethamine (A) 216; glimepiride (A) 1047; glucosamine (A) 576, 581; irinotecan (A) 1325; levofloxacin (A) 325; low-molecular-weight heparins (A) 105; mifepradil (A) 662; nadoparin (A) 593; ranitidine bismuth citrate (A) 674; sparflaxacin (A) 325; tiagabine (A) 1175; tinzaparin (A) 594; topotecan (A) 1336; troglitazone (A) 340; zinc acetate (A) 80; zinc lozenges, common cold (A) 65

**Clofazimine**, *Mycobacterium avium* complex (A) 568  
**Clozapine**, rhabdomyolysis (CR) 892; seizures (RR) 1147; state hospital use (A) 906  
**Colestipol**, compared with atorvastatin (A) 1033  
**Common cold**, zinc lozenges (A) 64  
**Compatibility**, dual-lumen catheter, delivery of incompatible medications (RR) 875; paclitaxel, with doxorubicin (RR) 1013  
**Compliance**, elderly (RR) 749  
**Concentrations**, carbamazepine, viral hepatitis (L) 1369; docetaxel, undetectable cerebrospinal fluid concentration (L) 611; vancomycin, Wragge-Cooper prediction method (RR) 176  
**Contraceptives**, adverse pregnancy outcomes (A) 802; antiepileptic drugs (A) 795  
**Coronary artery disease**, insulin (A) 233  
**Corrections**, abacimab, cost-effectiveness (L) 845; analysis of research literature (L) 612; azithromycin-induced SIADH (L) 388; ketogenic diet in children with intractable seizures (L) 1372  
**Creatinine clearance**, estimation, cardiac patients (RR) 1275  
**Critical care**, continuous renal replacement therapy (A) 362; Hartford nomogram, trauma surgery patients (RR) 417; stress ulcer prophylaxis, drug use vs. endoscopically proven ulceration (CR) 869  
**Cyclobenzaprine**, with droperidol and fluoxetine, torsade de pointes (CR) 761  
**Cyclosporine**, interaction, azole antifungals (A) 916  
**Cystitis**, acute, fosfomycin tromethamine (A) 215  
**Cytarabine hydrochloride**, pharmacokinetics, cerebrospinal fluid (RR) 1008  
**Cytomegalovirus**, atherosclerosis (A) 1310; cidofovir (A) 1181; retinitis, local therapy (A) 248

## D

**D'Arcy, Patrick F.**, Honorary Membership, International Pharmaceutical Federation (NC) 999  
**Dalteparin**, compared with unfractionated heparin, deep-vein thrombosis (A) 591; pharmacokinetics (A) 589; pharmacology (A) 589  
**Dapsone**, desensitization, *Pneumocystis carinii* prophylaxis (CR) 1302; methemoglobinemia (CR) 549  
**Database**, electronic prescription (RR) 1152  
**Deep-vein thrombosis**, low-molecular-weight heparins (A) 588  
**Dehydroepiandrosterone**, AIDS-associated wasting (A) 449  
**Depression**,  $\beta$ -blockers (A) 699; St. John's wort (*Hypericum*) (A) 1201  
**Desmopressin**, nocturia, enuresis, multiple sclerosis (A) 114  
**Diabetes mellitus**, type 2, glimepiride (A) 1044; type 2, glycemic control (A) 896; type 2, outpatient management by pharmacists (RR) 636  
**Dialysis**, children (A) 929; continuous cycling peritoneal, fluconazole pharmacokinetics (A) 1284; peritoneal, thrombolytic therapy for peritonitis (A) 1216  
**Diet**, ketogenic, intractable seizures (A) 349; ketogenic, multidisciplinary approach (E) 384  
**Digestive inhibitors**, obesity (A) 88  
**Digoxin**, interaction, azole antifungals (A) 918  
**Diltiazem**, acute interstitial nephritis (CR) 656; compared with mibefradil (A) 663  
**Dissolution**, methylphenidate extended-release (L) 1372  
**Diuretics**, end-stage renal disease, children (A) 933  
**Docetaxel**, undetectable cerebrospinal fluid concentration (L) 611  
**Dolasetron mesylate**, infusion rate, pharmacokinetics (RR) 39  
**Doluisio, James T.**, Clifton J. Latolais Honor Medal (NC) 1268  
**Donepezil**, adverse reactions (A) 73, cost (A) 74; pharmacokinetics (A) 71; pharmacology (A) 70; worsened Parkinson's disease (L) 610  
**Dopamine**, extravasation injury (CR) 545  
**Dosage**, ampicillin, low birth weight (A) 482; cidofovir (A) 1188; doxorubicin, hyperbilirubinemia of Gilbert's syndrome (CR) 1026; irinotecan (A) 1330; low-molecular-weight heparins (A) 590; ranitidine bismuth citrate (A) 676; tiagabine (A) 1178; topotecan (A) 1340; troglitazone (A) 345  
**Dosage form, intravenous**, dolasetron mesylate (RR) 39, fentanyl (CR) 316, ketorolac (CR) 193, vs. oral, phenytoin (RR) 300; lozenges, zinc (A) 63  
**Doxorubicin**, dosage, hyperbilirubinemia of Gilbert's syndrome (CR) 1026; with paclitaxel, compatibility and stability (RR) 1013  
**Draughals, Jolaine R.**, Distinguished Pharmacy Educator, AACP (NC) 518  
**Dronabinol**, AIDS-associated wasting (A) 449  
**Droperidol**, with cyclobenzaprine and fluoxetine, torsade de pointes (CR) 761  
**Drug abuse**, flunitrazepam (A) 117, 980 (L)  
**Drug information**, elderly (RR) 743; medical information service, Italy (A) 120; provision of useful information, Healthy People 2000 Plan (L) 612; written (A) 962  
**Drug information rounds**, acyclovir, neurotoxicity (A) 111; amphotericin B, test dose (A) 475; ampicillin, neurotoxicity, premature neonates (A) 482; botulinum toxin type A, frown lines, 1365; buspirone, smoking cessation, 1362; calcium, corticosteroid-induced osteoporosis (A) 970; carvedilol, heart

failure (A) 376; corticosteroids, herpes zoster pain (A) 1099; desmopressin, nocturia, enuresis, multiple sclerosis (A) 114; ganciclovir, neurotoxicity (A) 111; glucocorticoids, croup (A) 977; glutathione, trimethoprim/sulfamethoxazole hypersensitivity (A) 381; ketoconazole, cutaneous fungal infections (A) 709; losartan, renal dysfunction (A) 1096; low-molecular-weight heparin, pulmonary embolism (A) 258; nicotine, transdermal, cardiac disease (A) 264; omeprazole, children (A) 478; opioid antagonists, pruritus from liver disease (A) 1228; raloxifene, osteoporosis prophylaxis, 834; theophylline, bradycardia in elderly (A) 837; urinary tract infections, treatment (A) 1231; urokinase, intraventricular hemorrhage (A) 256  
**Drug interactions**, antiacids-azole antifungals, review (A) 923  
**Antidiabetic agents-azole antifungals**, review (A) 923  
**Antiepileptics**, review (A) 554  
**Antiretrovirals-azole antifungals**, review (A) 920  
**Atorvastatin**, review (A) 1038  
**Azithromycin**, review (A) 790  
**Azithromycin-warfarin** (L) 269, 844  
**Azole antifungals-antacids**, review (A) 923  
**Azole antifungals-antidiabetics**, review (A) 923  
**Azole antifungals-antiretrovirals**, review (A) 920  
**Azole antifungals-benzodiazepines**, review (A) 920  
**Azole antifungals-calcium-channel blockers**, review (A) 920  
**Azole antifungals-cisapride**, review (A) 916  
**Azole antifungals-corticosteroids**, review (A) 923  
**Azole antifungals-cyclosporine**, review (A) 916  
**Azole antifungals-digoxin**, review (A) 918  
**Azole antifungals-HMG-CoA reductase inhibitors**, review (A) 918  
**Azole antifungals-isoniazid**, review (A) 919  
**Azole antifungals-nonsedating antihistamines**, review (A) 915  
**Azole antifungals-phenytoin**, review (A) 919  
**Azole antifungals-protease inhibitors**, review (A) 920  
**Azole antifungals-quinidine**, review (A) 923  
**Azole antifungals-rifabutin**, review (A) 922  
**Azole antifungals-rifampin**, review (A) 919  
**Azole antifungals-succinylcholine**, review (A) 923  
**Azole antifungals-tacrolimus**, review (A) 916  
**Azole antifungals-warfarin**, review (A) 920  
**Benzodiazepines-azole antifungals**, review (A) 920  
**Bismuth salts-tetracycline** (L) 387  
**Calcium-channel blockers-azole antifungals**, review (A) 920, 916  
**Cisapride-azole antifungals**, review (A) 916  
**Corticosteroids-azole antifungals**, review (A) 923  
**Cyclobenzaprine-droperidol-fluoxetine** (CR) 761  
**Cyclosporine-azole antifungals**, review (A) 916  
**Digoxin-azole antifungals**, review (A) 918  
**Droperidol-cyclobenzaprine-fluoxetine** (CR) 761  
**Eprosartan-ranitidine**, no interaction (RR) 304  
**Fenofibrate-warfarin** (CR) 765  
**Fluoxetine-droperidol-cyclobenzaprine** (CR) 761  
**Glimepiride**, review (A) 1050  
**HMG-CoA reductase inhibitors-azole antifungals**, review (A) 918  
**Isoniazid-azole antifungals**, review (A) 919  
**Levofloxacin**, review (A) 330  
**Macrolides-verapamil** (L) 387  
**Mesalamine-warfarin** (L) 841  
**Mexiletine-omeprazole**, no interaction (RR) 182  
**Mibefradil**, review (A) 668  
**Nonsedating antihistamines-azole antifungal agents**, review (A) 915  
**Omeprazole-mexiletine**, no interaction (RR) 182  
**Phenytoin-azole antifungals**, review (A) 919  
**Phenytoin-ticlopidine** (CR) 1295  
**Protease inhibitors-azole antifungals**, review (A) 920  
**Quinidine-azole antifungals**, review (A) 923  
**Ranitidine bismuth citrate**, review (A) 675  
**Ranitidine-eprosartan**, no interaction (RR) 304  
**Rifabutin-azole antifungals**, review (A) 922  
**Rifampin-azole antifungals**, review (A) 919  
**Ritonavir-warfarin** (CR) 1299  
**Sparfloxacin**, review (A) 330  
**Succinylcholine-azole antifungals**, review (A) 923  
**Tacrolimus-azole antifungals**, review (A) 916  
**Tetracycline-bismuth salts** (L) 387  
**Ticlopidine-phenytoin** (CR) 1295  
**Verapamil-macrolides** (L) 387  
**Warfarin-azithromycin** (L) 269, 844  
**Warfarin-azole antifungals**, review (A) 920  
**Warfarin-fenofibrate** (CR) 765  
**Warfarin-mesalamine** (L) 841  
**Warfarin-ritonavir** (CR) 1299  
**Drug selection perspectives**, low-molecular-weight heparins, acute coronary syndrome (A) 103, deep-vein thrombosis (A) 588; nicotine replacement (A) 1067; obesity (A) 88; thrombolytic agents (A) 769  
**Drug therapy decisions**, evidence-based practice (A) 1193  
**Drug utilization review**, disease-based, compared with Medicaid, asthma (RR) 1290  
**Drugs, adverse reactions**, acyclovir, neurotoxicity (A) 111; alendazole, thrombocytopenia (L) 842; amiodarone, granuloma (CR) 60; amiodipine, neuromuscular complications (CR) 1165; ampicillin, neurotoxicity, premature neonates (A) 482; antimalarial drugs (O) 1104; aspirin, burn of oral cavity (VO) 1107; atorvastatin, review (A) 1037; azathioprine, hypersensitivity (CR) 425;  $\beta$ -blockers, depression (A) 699; bupivacaine,

respiratory depression (CR) 653; carbamazepine, rash, blood dyscrasias (CR) 884; chloroquine, hepatitis (CR) 1023; cidofovir, review (A) 1187; cisapride, syncope, QT prolongation (CR) 648; clarithromycin, leukocytoclastic vasculitis (CR) 543; clindamycin phosphate, *Clostridium difficile* toxin colitis (CR) 309; clozapine, rhabdomyolysis (CR) 892; clozapine, seizures (RR) 1147; dapsone, methemoglobinemia (CR) 549; diltiazem, acute interstitial nephritis (CR) 656; donepezil, review (A) 73; donepezil, worsened Parkinson's disease (L) 610; dopamine, extravasation injury (CR) 545; fluoxetine, serotonin syndrome (CR) 432; fosfomycin tromethamine, review (A) 217; ganciclovir, neurotoxicity (A) 111; glimepiride, review (A) 1049; glucosamine, review (A) 578; heparin, thrombocytopenia (CR) 55; indinavir, interstitial nephritis (L) 843; indomethacin, behavioral changes (CR) 201; irinotecan, review (A) 1328; isoniazid, psychosis (CR) 889; itraconazole, serum sickness-like reaction (L) 1249; lansoprazole, eosinophilic syndrome (CR) 196; latanoprost, ocular hypertension (L) 504; levamisole, psychosis (L) 134; levofloxacin, review (A) 329; losartan, hepatotoxicity (L) low-molecular-weight heparins, review (A) 596; magnesium hydroxide, hypermagnesemia (CR) 312; medroxyprogesterone acetate, adrenal insufficiency (L) 134; methotrexate, cutaneous ulceration (CR) 651; metoclopramide, respiratory failure (CR) 1017; metronidazole, peripheral neuropathy (L) 267; mibefradil, review (A) 667; minocycline, tooth staining (CR) 887; nelfinavir, hyperglycemia (L) 609; nonsteroidal antiinflammatory drugs, hepatitis (VO) 386; olanzapine, neuroleptic malignant syndrome (CR) 1158; oxybutynin, night terror (L) 506; pemoline, liver failure (CR) 422; penicillamine, bullous pemphigoid (VO) 1368; placebo vs. active drug (L) 132; ranitidine bismuth citrate, review (A) 675; recombinant human growth hormone, review (A) 442; risperidone, hepatotoxicity (L) 843; salbutamol, lingual lesions (VO) 1248; selective serotonin-reuptake inhibitors, movement disorders (A) 692, (O) 712; sparfloxacin, review (A) 329; stavudine, gynecostasia (L) 1108; sulfamethoxazole, with trimethoprim, metabolic acidosis (CR) 185, tremor (CR) 189; sumatriptan, serotonin syndrome, risk (RR) 33; tetracycline, tooth staining (VO) 607; thrombolytics, review (A) 779; tiagabine, review (A) 1178; ticlopidine, hepatotoxicity (L) 1250 (L) 1370; topotecan, review (A) 1339; tretinoin, topical, congenital malformations (L) 505; trimethoprim, with sulfamethoxazole, metabolic acidosis (CR) 185, tremor (CR) 189; troglitazone, review (A) 344; valproic acid, increased seizure activity (CR) 1168; vancomycin, acute interstitial nephritis (CR) 1160, red man syndrome (VO) 840; venlafaxine, hyponatremia (CR) 49, (L) 981, seizure (L) 135, serotonin syndrome (CR) 432; vinorelbine, syndrome of inappropriate antidiuretic hormone (A) 1306; zinc acetate, review (A) 83

## E-F

**Editorials**, see also: **Opinions**: Graves, Nina M., Gidal, Barry E., Gilliam, Frank G., The New Generation of Antiepileptic Drugs: Unresolved Questions (E) 1239; Heyneman, Catherine A., Rhodes, Richard S., Glucosamine for Osteoarthritis: Cure or Conundrum?, 602; Howie, Denise L., Kraisinger, Marijo, McGhee, H. William, Crumrine, Patricia K., Katyal, Neelam, The Ketogenic Diet: The Need for a Multidisciplinary Approach, 384; Nahata, Milap C., Welty, Timothy E., Troubling Issues with Research Publications, 126  
**Education**, healthcare practitioners, use of literature (A) 829  
**Educational events**, 146, 278, 396, 515, 621, 729, 856, 996, 1127, 1266, 1380  
**Endothelial dysfunction**, review (A) 459  
**Enoxaparin**, compared with unfractionated heparin, deep-vein thrombosis (A) 593; pharmacokinetics (A) 590; pharmacology (A) 589  
**Epidemiology**, *Candida* spp. (A) 1353; *Mycobacterium avium* complex, HIV (A) 564  
**Epilepsy**, tiagabine (A) 1173; treatment challenges (E) 1239; women of childbearing age (A) 794  
**Epstein alfa**, end-stage renal disease, children (A) 931  
**Eprosartan**, no interaction, ranitidine (RR) 304  
**Equations**, creatinine clearance estimation, cardiac patients (RR) 1275  
**Estrogen**, endothelial dysfunction (A) 464  
**Ethambutol**, *Mycobacterium avium* complex (A) 567  
**Ethosuximide**, drug interactions, review (A) 559  
**Eite, Ene I.**, expert consultant, Center for Drug Evaluation and Research, FDA (NC) 626  
**Extravasation**, parenteral nutrition, hyaluronidase (CR) 51; with dopamine (CR) 545  
**Felbamate**, drug interactions, review (A) 559  
**Fellowships and residences**, California, University of Southern California, 1265, 1379; Nebraska, Creighton University, 150, 1126, 1265; Ohio, Rainbow Babies and Children's Hospital, 1379  
**Fenofibrate**, interaction, warfarin (CR) 765  
**Fentanyl**, continuous infusion, severe pain (CR) 316  
**Fluconazole**, intraperitoneal, pharmacokinetics (A) 1284; onychomycosis (A) 209  
**Flunitrazepam**, abuse (L) 980; amnesic action (A) 117  
**Fluorouracil**, with irinotecan, colorectal cancer (A) 1327

**Fluoxetine**, serotonin syndrome (CR) 432; with droperidol and cyclobenzaprine, torsade de pointes (CR) 761  
**Folate**, adverse pregnancy outcomes (A) 802  
**Folic acid**, consumption, women of childbearing age (NC) 624; pharmacology, economics (A) 1087; pregnancy (A) 947  
**Food**, effect on gabapentin absorption (RR) 405  
**Formulary forum**, atorvastatin (A) 1030; cidofovir (A) 1181; donepezil, Alzheimer disease (A) 70; fosfomycin tromethamine, acute cystitis (A) 215; glimepiride (A) 1044; glucosamine (A) 574; irinotecan (A) 1324; levofloxacin (A) 320; mibefradil (A) 659; ranitidine bismuth citrate (A) 672; recombinant human growth hormone (A) 437; sparfloxacin (A) 320; tiagabine (A) 1173; topotecan (A) 1334; troglitazone, diabetes mellitus (A) 337; zinc acetate, Wilson's disease (A) 78  
**Foscarnet**, intravitreal, cytomegalovirus retinitis (A) 251  
**Fosfomycin tromethamine**, pharmacokinetics (A) 216

## G-H

**Gabapentin**, absorption, effect of food (RR) 405; drug interactions, review (A) 560  
**Ganciclovir**, intravitreal, intraocular, cytomegalovirus retinitis (A) 248; neurotoxicity (A) 111  
**Gans**, John A, Harvey AK Whitney Lecture Award (NC) 732  
**Gastroenterology**, medication bezoars (A) 940  
**General medicine**, dual-lumen peripheral catheter, incompatible medications (RR) 875; health behaviors (A) 1076; pharmaceutical care, cost, number of adverse reactions (RR) 294  
**General**, Joyce, editor, Clin Alert (NC) 280  
**Genetics**, clinical aspects (O) 977  
**Geriatrics**, bradycardia, theophylline (A) 837; carbamazepine, rash, blood dyscrasias (CR) 884; compliance (RR) 749; drug information (RR) 743; indomethacin (L) 980, behavioral changes (CR) 201  
**Geriatrics and gerontology**, prescribing outcomes, Swedish nursing homes (RR) 27; pressure ulcers, treatment (A) 1221  
**Glimepiride**, adverse reactions (A) 1049; cost (A) 1050; interactions (A) 1046; pharmacodynamics (A) 1046; pharmacokinetics (A) 1045  
**Glucosamine**, adverse reactions (A) 578; compared with ibuprofen (A) 577, (A) 584; literature review, exclusion criteria, (E) 602, (L) 1371; pharmacokinetics (A) 575; pharmacology (A) 575  
**Glutathione**, trimethoprim/sulfamethoxazole hypersensitivity (A) 381  
**Granuloma**, amiodarone (CR) 60  
**Graphics**, statistical, pharmacokinetics (A) 818  
**Growth hormone**, end-stage renal disease, children (A) 932  
**Guar gum**, bezoars (A) 943  
**Heart failure**, carvedilol therapy (A) 376; endothelial dysfunction (A) 465; mortality rates (NC) 1129  
**Helicobacter pylori**, ranitidine bismuth citrate (A) 672  
**Heparin**, low-molecular-weight, acute coronary syndrome (A) 103, deep-vein thrombosis (A) 588, pulmonary embolism (A) 258; nomogram, weight-based modification (L) 715; thrombocytopenia (CR) 55; with aspirin, death of pregnant woman (NC) 860  
**Hepatitis**, carbamazepine concentrations (L) 1369; nonsteroidal antiinflammatory drugs (VO) 386  
**Herpes zoster**, corticosteroids for pain (A) 1099  
**Herpesvirus**, cidofovir (A) 1184  
**HIV**, see **Human immunodeficiency virus**  
**Hormonal manipulation**, obesity (A) 88  
**Human immunodeficiency virus**, cost-effectiveness of care (L) 716; disseminated *Mycobacterium avium* complex, prophylaxis and treatment (A) 564; glutathione, trimethoprim/sulfamethoxazole hypersensitivity (A) 381; rapid tests, counseling (NC) 625; trimethoprim/sulfamethoxazole, metabolic acidosis (CR) 185; zidovudine, with lamivudine or zalcitabine, quality of life (RR) 525  
**Hyaluronidase**, extravasation, parenteral nutrition (CR) 51  
**Hydroxymethylglutaryl coenzyme A reductase inhibitors**, interaction, azole antifungals (A) 918  
**Hypercholesterolemia**, atorvastatin, review (A) 1030  
**Hypericum**, see **St. John's wort**  
**Hypermagnesemia**, magnesium hydroxide (CR) 312  
**Hypertension**, endothelial dysfunction (A) 466; insulin (A) 236; mibefradil (A) 662  
**Hypnotics**, nonbenzodiazepine, tranquilizers (RR) 531  
**Hypnotics**, nonbenzodiazepine, insomnia (A) 680  
**Hypnatremia**, venlafaxine (CR) 49, (L) 981

## I-L

**Ibuprofen**, compared with glucosamine (A) 577; compared with glucosamine (A) 584  
**Immunizations**, recommended schedule (NC) 397  
**Immunology**, adjuvant, toxicity management (A) 1344  
**India**, drug advertising (A) 1234  
**Indinavir**, interstitial nephritis (L) 843

**Indomethacin**, behavioral changes (CR) 201; elderly (L) 980  
**Infectious diseases**, arboviral infections, CNS (NC) 998; atovaquone, with enteral nutrition, bioavailability (RR) 1004; azithromycin, compared with clarithromycin and erythromycin (A) 785; azole antifungal agents, drug interactions (A) 915;  $\beta$ -lactam/ $\beta$ -lactamase inhibitors, community-acquired pneumonia (A) 522; *Candida* infections, therapeutic options (A) 1353; community-acquired infections, cost-effective treatment (A) 527; fluconazole, intraperitoneal, pharmacokinetics (A) 1284; HIV, disseminated *Mycobacterium avium* complex (A) 564; ketoconazole, cutaneous fungal infections (A) 709; onychomycosis, review (A) 204; *Staphylococcus aureus*, nosocomial infection (A) 57; zidovudine, with lamivudine or zalcitabine, quality of life (RR) 525  
**Influenza**, occurrence rate (NC) 624  
**Insulin**, coronary artery disease (A) 233; hypertension (A) 236; resistance, lipid disorders (A) 235, obesity (A) 235, pathogenesis (A) 234; smoking (A) 237  
**International reports**, India, drug advertisements (A) 1234; Italy, medical information service (A) 120; Sweden, prescription and nonprescription analgesics (A) 485  
**Irinotecan**, adverse reactions (A) 1328; cost (A) 1330; dosage (A) 1330; pharmacokinetics (A) 1325; with fluorouracil (A) 1327  
**Iron**, end-stage renal disease, children (A) 932  
**Isoniazid**, induced psychosis (CR) 889; interaction, azole antifungals (A) 919  
**Italy**, medical information service (A) 120  
**Itraconazole**, onychomycosis (A) 207; serum sickness-like reaction (L) 1249  
**Jeffrey**, Louis P, honorary president, American Pharmaceutical Association (NC) 155  
**Journal received**, 138  
**Kenyon**, George L, dean, University of Michigan College of Pharmacy (NC) 626  
**Ketoconazole**, cutaneous fungal infections (A) 709  
**Ketorolac tromethamine**, central intravenous infusion, bone pain (CR) 193; repackaging syringes (L) 1252  
**Kidney failure**, children, management (A) 929  
**Koda-Kimble**, Mary Anne, board of directors, ACPE (NC) 518  
**Kreling**, David H, Fellow, American Pharmaceutical Association (NC) 280  
**Lamivudine**, with zidovudine, quality of life (RR) 525  
**Lamotrigine**, drug interactions, review (A) 559  
**Lansoprazole**, eosinophilic syndrome (CR) 196  
**Latanoprost**, topical, ocular hypertension (L) 504  
**Laxatives**, bezoars (A) 942  
**Levamisole**, psychosis (L) 134  
**Levofloxacin**, adverse reactions (A) 329; *Mycobacterium tuberculosis* (L) 268; pharmacokinetics (A) 323  
**Literature**, research, analysis (RR) 17; research, ethics, sponsor control (E) 126; structured abstracts (O) 1244  
**Losartan**, hepatotoxicity (L) 1371; renal dysfunction (A) 1096  
**Lovastatin**, compared with atorvastatin (A) 1034

## M-O

**Macrolides**, interaction, voraqamyl (L) 387; *Mycobacterium avium* complex (A) 566  
**Magnesium hydroxide**, hypermagnesemia (CR) 312  
**Manasse**, Henri R Jr, medical and healthcare advisor, Healthcare Inspections Office, Department of Veterans Affairs (NC) 280  
**Marijuana**, AIDS-associated wasting (A) 449  
**Medicaid**, compared with disease-based DUR, asthma (RR) 1290  
**Medroxyprogesterone acetate**, adrenal insufficiency (L) 134  
**Megestrol acetate**, AIDS-associated wasting (A) 450  
**Melatonin**, insomnia (A) 687  
**Mesalamine**, interaction, warfarin (L) 841  
**Methemoglobinemia**, dapson (CR) 549  
**Methotrexate**, cutaneous ulceration (CR) 651; pharmacokinetics, cerebrospinal fluid (RR) 1008  
**Methylphenidate**, extended-release, dissolution (L) 1372  
**Metoclopramide**, respiratory failure (CR) 1017  
**Metronidazole**, peripheral neuropathy (L) 267  
**Mexiletine**, no interaction, omeprazole (RR) 182  
**Mibefradil**, adverse reactions (A) 667; angina (A) 665; compared with amlodipine (A) 664; compared with diltiazem (A) 663; compared with nifedipine (A) 664; compared with verapamil (A) 663; drug interactions (A) 668; pharmacodynamics (A) 661; pharmacokinetics (A) 661; pharmacology (A) 660; withdrawal (L) 1372; withdrawn from market (L) 841  
**Minocycline**, tooth staining (CR) 887  
**Multiple sclerosis**, nocturia, enuresis, desmopressin (A) 114  
***Mycobacterium avium* complex**, clofazimine (A) 568; epidemiology (A) 565; ethambutol (A) 567; etiology (A) 564; macrolides (A) 566; prophylaxis (A) 569; quinolones (A) 567; rifamides (A) 568  
***Mycobacterium tuberculosis***, levofloxacin (L) 268  
**Mycophenolate mofetil**, stability (RR) 755; with corticosteroids, liver transplant (CR) 45  
**Myocardial infarction**, angiotensin-converting enzyme inhibitors, effect of prior therapy (RR) 1141; cytomegalovirus,

*Chlamydia pneumoniae* (A) 1310; low-molecular-weight heparins (A) 103; thrombolytic therapy (A) 769  
**Nadroparin**, compared with unfractionated heparin, deep-vein thrombosis (A) 593; pharmacokinetics (A) 590; pharmacology (A) 589  
**Nalmefene**, pruritus from liver disease (A) 1229  
**Naloxone**, pruritus from liver disease (A) 1229  
**Naltrexone**, pruritus from liver disease (A) 1229  
**Nandrolone**, AIDS-associated wasting (A) 452  
**Nefazodone**, overdose (L) 1249  
**Nelfinavir**, hyperglycemia (L) 609  
**Nephrology**, continuous renal replacement therapy (A) 362; creatinine clearance estimation, cardiac patients (RR) 1275; end-stage renal disease, children (A) 929; peritoneal dialysis, peritonitis (A) 1216  
**Neuroleptic malignant syndrome**, olanzapine (CR) 1158  
**Neurology**, epilepsy, women of childbearing age (A) 794; gabapentin, absorption after food intake (RR) 405; propofol, status epilepticus (A) 1053  
**Neuropsychiatry**, hypnotics, nonbenzodiazepine, insomnia (A) 680; sumatriptan, serotonin syndrome, risk (RR) 33  
**Niacin**, compared with atorvastatin (A) 1034  
**Nicotine**, pharmacodynamics (A) 1068; pharmacokinetics (A) 1068; transdermal, heart disease (A) 264; withdrawal (A) 1069  
**Nifedipine**, compared with mibefradil (A) 664  
**Nimustine**, pharmacokinetics, cerebrospinal fluid (RR) 1008  
**Nomograms**, Hartford, trauma surgery patients (RR) 417, validation (L) 1108  
**Nutrition**, enteral, AIDS-associated wasting (A) 448; continuous vs. interrupted feeding, effect on tacrolimus absorption (RR) 633; parenteral, AIDS-associated wasting (A) 449, extravasation, hyaluronidase (CR) 51  
**Obesity**, appetite suppressants (A) 90; digestive inhibitors (A) 95; hormonal manipulation (A) 99; insulin resistance (A) 235; thermogenic agents (A) 94  
**Obstetrics/gynecology**, antiepileptics, contraceptives, smoking, folate (A) 802; folic acid (A) 947; pharmacology, economics (A) 1087  
**Olanzapine**, neuroleptic malignant syndrome (CR) 1158; state hospital use (A) 907  
**Omeprazole**, children (A) 478; no interaction, mexiletine (RR) 182  
**Oncology**, paclitaxel, with doxorubicin, compatibility and stability (RR) 1013; pharmacokinetics in cerebrospinal fluid (RR) 1008; pleurodesis, iodized talc, malignant effusions (RR) 739  
**Onychomycosis**, fluconazole (A) 209; itraconazole (A) 207; pulse therapy (A) 209; review (A) 204; terbinafine (A) 207  
**Opinions**, see also **Editorials**; **Davis**, Timothy ME, **Adverse Effects of Antimalarial Prophylactic Drugs: An Important Consideration in the Risk-Benefit Equation**, 1104; **Grabenstein**, John D, **Should Vaccines require a Prescription?**, 495; **Kneiff**, Daren L, **Clinical Aspects of Gene Therapy**, 977; **Leo**, **Raphael J**, **Movement Disturbances Associated with the Use of Selective Serotonin-Reuptake Inhibitors**, 712; **Mittmann**, Nicole, **Trakas**, Kostas, **Iskedjian**, Michael, **Bradley**, Carol A, **Einarson**, Thomas R, **A Proposal for Structured Abstracts of Health Economic Studies**, 1244; **Schlicht**, John R, **Giannetti**, Vincent J, **Reasons to Question Psychologist Prescribing**, 129  
**Osteoporosis**, corticosteroid-induced, calcium (A) 970; prophylaxis, raloxifene (A) 834  
**Outcomes**, regulation (RR) 642  
**Oxandrolone**, AIDS-associated wasting (A) 452  
**Oxybutynin**, night terror (L) 506

## P

**Packaging**, ketorolac tromethamine syringes (L) 1252  
**Paclitaxel**, with doxorubicin, compatibility and stability (RR) 1013  
**Pain**, fentanyl, continuous infusion (CR) 316; herpes zoster, corticosteroids (A) 1099; ketorolac, continuous intravenous infusion (CR) 194  
**Parker**, Paul F, obituary (NC) 862  
**Parkinson's disease**, donepezil aggravated (L) 610; Sinemet CR compared with standard Sinemet, cost (RR) 878  
**Patient education**, written (A) 962  
**Pediatrics**, ampicillin, neurotoxicity, premature neonates (A) 482; end-stage renal disease (A) 929; infant mortality, birth defects (NC) 1267; ketogenic diet, seizures (A) 349; omeprazole use (A) 478; pediatric drug data, FDA list (NC) 731; pemoline-induced liver failure (A) 422; pharmacology research (NC) 154; premature neonates, phenytoin concentrations (RR) 300; tiagabine (A) 1177  
**Pemoline**, liver failure (CR) 422  
**Penicillamine**, bullous pemphigoid (VO) 1368  
**Peptic ulcer disease**, causes (NC) 153  
**Pharmaceutical care**, regulation of pharmaceutical care outcomes (RR) 642; research literature (RR) 17  
**Pharmacodynamics**, glimepiride (A) 1046; mibefradil (A) 661; nicotine (A) 1068; topotecan (A) 1335  
**Pharmacoeconomics**, cost, antiepileptics (E) 1242; atorvastatin (A) 1039; cidofovir (A) 1188, consultant pharmacist services

(NC) 153; cytomegalovirus retinitis (A) 253; donepezil (A) 74; folic acid (A) 1087; glimepiride (A) 1050; irinotecan (A) 1330; ketogenic diet (A) 354; levofloxacin (A) 330; low-molecular-weight heparins (A) 591; novel antipsychotics (A) 910; onychomycosis (A) 211; recombinant human growth hormone (A) 442; Sinemet CR compared with standard Sinemet (RR) 878; sparflaxacin (A) 330; tiagabine (A) 1179; topotecan (A) 1340; troglitazone (A) 345; zinc acetate (A) 86; cost-effectiveness, abacavir (RR) 536, HIV disease care (L) 716; treatment of community-acquired infections (A) 527; structured abstracts (O) 1244

**Pharmacoeconomics**, prescription database, electronic (RR) 1152

**Pharmacokinetics**, atorvastatin (A) 1032; azithromycin (A) 787; cidofovir (A) 1183; continuous renal replacement therapy (A) 369; corticosteroids, inhaled (A) 222; cytarabine hydrochloride, cerebrospinal fluid (A) 1008; dalteparin (A) 591; delosolone mesylate, infusion rate (RR) 39; donepezil (A) 71; enoxaparin (A) 591; eprosartan, effect of ranitidine (RR) 304; fluconazole, intraperitoneal (A) 1284; fosfomycin tromethamine (A) 216; glimepiride (A) 1046; glucosamine (A) 575; irinotecan (A) 1325; levofloxacin (A) 323; methotrexate, cerebrospinal fluid (RR) 1008; mifepristide (A) 661; nadroparin (A) 593; nicotine (A) 1068; nimustine, cerebrospinal fluid (RR) 1008; pirarubicin (L) 269; ranitidine bismuth citrate (A) 673; sparflaxacin (A) 323; statistical graphics (A) 818; tiagabine (A) 1175; ticarcillin/clavulanic acid (A) 518; tinzaparin (A) 589; topotecan (A) 1335; troglitazone (A) 340; zinc acetate (A) 80

**Pharmacology**, atorvastatin (A) 1032; dalteparin (A) 589; donepezil (A) 70; enoxaparin (A) 589; glimepiride (A) 1045; glucosamine (A) 575; mifepristide (A) 660; nadroparin (A) 589; ranitidine bismuth citrate (A) 673; St. John's wort (*Hypericum*) (A) 1203; terbinafine (A) 206; tiagabine (A) 1174; tinzaparin (A) 589; troglitazone (A) 339; zinc acetate (A) 80

**Pharmacotherapy**, evidence-based (A) 1193

**Phenobarbital**, drug interactions, review (A) 557; pregnancy (A) 810

**Phenytoin**, concentrations, premature neonates (RR) 300; interaction, review (A) 556; azole antifungals (A) 919; ciprofloxacin (L) 1110; ti-lodipine (CR) 1295; pregnancy (A) 806

**Phosphate binders**, end-stage renal disease, children (A) 935

**Pirarubicin**, pharmacokinetics (L) 269

**Placebo**, adverse reactions, generalized anxiety disorder (L) 132

**Pleurodesis**, iodized talc, malignant effusions (RR) 739

***Pneumocystis carinii***, prophylaxis, dapsone desensitization (CR) 1302

**Pneumonia**, community-acquired,  $\beta$ -lactam/ $\beta$ -lactamase inhibitors (A) 522

**Ponte, Charles D.**, Fellow, American Pharmaceutical Association (NC) 280

**Pravastatin**, compared with atorvastatin (A) 1036

**Prescribing**, concomitant, tranquilizers and hypnotics (RR) 531; psychologist (O) 129; ticarcillin/clavulanic acid (A) 517

**Primidone**, drug interactions, review (A) 557; pregnancy (A) 810

**Prophylaxis**, antimarial, dapsone desensitization (CR) 1302; stress ulcers, drug use vs. endoscopically proven ulceration (RR) 869

**Propofol**, status epilepticus (A) 1053

**Protease inhibitors**, interaction, azole antifungals (A) 920

**Psychiatry**, carbamazepine, rash, blood dyscrasias (CR) 884; clozapine, seizures (RR) 1147; novel antipsychotics, state hospital use (A) 906; prescribing, tranquilizers and hypnotics (RR) 531; selective serotonin-reuptake inhibitors, movement disorders (A) 692; sexual dysfunction (A) 1209; St. John's wort (*Hypericum*) (A) 1201

**Psychologists**, prescribing (O) 129

**Psychosis**, isoniazid-induced (CR) 889; levamisole (L) 134

**Pulmonary and allergy**, asthma, Medicaid compared with disease-based DUR (RR) 1290; corticosteroids, inhaled (A) 220

## Q-S

**Quality of life**, HIV, impact of zidovudine with lamivudine or zalcitabine (RR) 525

**Quetiapine**, state hospital use (A) 907

**Quinolone**, interaction, azole antifungals (A) 923

**Quinolones**, *Mycobacterium avium* complex (A) 567

**Raloxifene**, osteoporosis prophylaxis (A) 834

**Ranitidine**, no interaction, eprosartan (RR) 304; stress ulcer prophylaxis (RR) 869

**Ranitidine bismuth citrate**, adverse reactions (A) 675; drug interactions (A) 675; pharmacokinetics (A) 673; pharmacology (A) 673

**Recombinant human growth hormone**, adverse effects (A) 442; AIDS-associated wasting (A) 437; (A) 453; clinical trials (A) 439; cost (A) 442

**Resistance**, antibiotics, urinary tract infections (A) 1231; vancomycin, *Staphylococcus aureus* (CR) 758

**Retepase**, compared with alteplase, anistreplase, streptokinase, myocardial infarction (A) 769

**Rheumatology**, glucosamine sulfate, osteoarthritis (A) 580

**Rho Chi Lecture**, essential societal role (A) 471

**Rifabutin**, interaction, azole antifungals (A) 922

**Rifamides**, *Mycobacterium avium* complex (A) 568

**Rifampin**, false-positive urine melanin pigment (L) 610; interaction, azole antifungals (A) 919

**Risperidone**, hepatotoxicity (L) 843; hypotension, orthostasis (L) 267; state hospital use (A) 907

**Ritonavir**, interaction, warfarin (CR) 1299

**Salsalate**, lingual lesions (VO) 1248

**Seizures**, clozapine-induced (RR) 1147; ketogenic, children (A) 349; (L) 1373; valproic acid, increased activity (CR) 1168; venlafaxine (L) 135

**Selective serotonin-reuptake inhibitors**, movement disorders (A) 692; (O) 712; sexual dysfunction (A) 1209

**Serotonin syndrome**, risk, sumatriptan (RR) 33

**Sexual dysfunction**, selective serotonin-reuptake inhibitors (A) 1209

**Simvastatin**, compared with atorvastatin (A) 1036

**Smoking**, adverse pregnancy outcomes (A) 802; buspirone (A) 1362; epidemiologic report, racial/ethnic groups (NC) 731; insulin (A) 237

**Soflaxacin**, adverse reactions (A) 329; pharmacokinetics (A) 323

**St. John's wort**, depression (A) 1201; pharmacology (A) 1201

**Stability**, mycophenolate mofetil (RR) 755; paclitaxel, with doxorubicin (RR) 1013

***Staphylococcus aureus***, nosocomial infection, treatment (A) 57; resistance, vancomycin (CR) 758

**Status epilepticus**, propofol (A) 1053

**Stevia**, gynecomastritis (L) 1108

**Steroids, corticosteroids**, comparative studies (A) 224; croup (A) 973; herpes zoster pain (A) 1099; inhaled, pharmacokinetics (A) 222; interaction, azole antifungals (A) 923; osteoporosis, calcium (A) 970; with mycophenolate mofetil, liver transplant (CR) 45

***Streptococcus***, group B, hospital prophylaxis policies (NC) 1129

**Streptokinase**, compared with alteplase, anistreplase, reteplase, myocardial infarction (A) 769; peritoneal dialysis-associated peritonitis (A) 1217

**Sucralfate**, bezoars (A) 943; interactions, azole antifungals (A) 923; stress ulcer prophylaxis (RR) 869

**Sulfamethoxazole**, with trimethoprim, hypersensitivity, glutathione (A) 381; metabolic acidosis (CR) 185; tremor (CR) 189

**Sumatriptan**, serotonin syndrome, risk (RR) 33

**Supernaw, Robert B.**, professor, associate dean for Curriculum and Students, Texas Tech University Health Sciences Center (NC) 861

**Sweden**, analgesics, prescription patterns (A) 485; nursing homes, prescribing outcomes (RR) 27

**Sylvester, Mario F.**, director, ACCP research (NC) 732

**Sympatholytic agents**,  $\alpha$ -adrenergic blockers, end-stage renal disease, children (A) 935; depression (A) 699; end-stage renal disease, children (A) 934

## T

**Tacrolimus**, absorption, continuous vs. interrupted enteral feeding (RR) 633; interaction, azole antifungals (A) 916

**Talc, iodized**, pleurodesis, malignant effusions (RR) 739

**Terbinafine**, onychomycosis (A) 207; pharmacology (A) 206

**Testosterone**, AIDS-associated wasting (A) 452

**Tests**, laboratory, error limits (RR) 170

**Tetracycline**, interaction, bismuth salts (L) 387; tooth staining (VO) 607

**Thalidomide**, AIDS-associated wasting (A) 451

**Theophylline**, bradycardia in elderly (A) 837

**Therapeutic controversies**, chemotherapy, fever and neutropenia management (A) 1317; cytomegalovirus retinitis, local therapy (A) 248; cytomegalovirus, *Chlamydia pneumoniae*, atherosclerosis (A) 1310; diabetes mellitus, type 2, glycemic control (A) 896; zinc lozenges, common cold (A) 63

**Therapeutic monitoring**, Hartford nomogram, trauma surgery patients (RR) 417; laboratory error limits (RR) 170; vancomycin, Wragge-Cooper concentration prediction (RR) 176

**Thrombotic agents**, obesity (A) 94

**Thrombocytopenia**, albendazole (L) 842; heparin (CR) 55

**Thrombolytics**, adverse reactions (A) 779; review (A) 769

**Tiagabine**, adverse reactions (A) 1178; children (A) 1177; cost (A) 1179; dosage (A) 1178; drug interactions, review (A) 560; pharmacokinetics (A) 1175; pharmacology (A) 1174

**Ticarcillin/clavulanic acid**, pharmacokinetics (A) 518; prescribing (A) 517

**Ticlopidine**, hepatotoxicity (L) 1250; (L) 1370; interaction, phenytoin (CR) 1295

**Tinzaparin**, compared with unfractionated heparin, deep-vein thrombosis (A) 594; pharmacokinetics (A) 590; pharmacology (A) 589

**Topiramate**, drug interactions, review (A) 560

**Topotecan**, adverse reactions (A) 1339; dosage (A) 1340; pharmacodynamics (A) 1335; pharmacokinetics (A) 1335

**Townsend Raymond J.**, foundation of Strategic Outcomes Services LLC (NC) 1393

**Toxicity**, aldesleukin, management (A) 1346; chromium picolinate, overdose (CR) 428; heparin and aspirin, death of pregnant woman (NC) 860; nefazodone, overdose (L) 1249; risperidone, hypotension, orthostasis (L) 267

**Tranquilizers**, concomitant prescribing, hypnotics (RR) 531

**Transplantation**, liver, mycophenolate mofetil/corticosteroids (CR) 45; mycophenolate mofetil, stability (RR) 755; tacrolimus absorption, continuous vs. interrupted enteral nutrition (RR) 633

**Tretinoin**, topical, congenital malformations (L) 505

**Trimethoprim**, with sulfamethoxazole, hypersensitivity, glutathione (A) 381; metabolic acidosis (CR) 185; tremor (CR) 189

**Troglitazone**, adverse reactions (A) 344; chemistry (A) 338; dosage (A) 345; interactions (L) 1111; pharmacokinetics (A) 340; pharmacology (A) 339

**Tuberculosis**, drug resistance (NC) 860; morbidity (NC) 731; vaccines (NC) 1130

## U-Z

**Ulcers, duodenal**, ranitidine bismuth citrate (A) 672; pressure, management in the elderly (A) 1221; stress, drug prophylaxis vs. endoscopically proven ulcer (RR) 869

**Urinary tract infections**, antibiotic resistance (A) 1231

**Urokinase**, intraventricular hemorrhage (A) 256; peritoneal dialysis-associated peritonitis (A) 1217

**Vaccination**, coverage levels, July 1996-June 1997 (NC) 517; elderly persons (NC) 1390; end-stage renal disease, children (A) 936

**Vaccines**, prescription requirements (O) 495; tuberculosis (NC) 1130; unlicensed combination (NC) 1267

**Valerian**, insomnia (A) 686

**Valproate**, drug interactions, review (A) 558

**Valproic acid**, increased seizure activity (CR) 1168; pregnancy (A) 809

**Vancomycin**, acute interstitial nephritis (CR) 1160; concentrations, Wragge-Cooper prediction method (RR) 176; desensitization (CR) 1020; red man syndrome (VO) 840; resistance, *Staphylococcus aureus* (CR) 758

**Vasodilators**, end-stage renal disease, children (A) 935

**Venlafaxine**, hyponatremia (CR) 49; (A) 981; seizure (L) 135; serotonin syndrome (CR) 432

**Verapamil**, compared with mifepristide (A) 663; interactions, macrolides (L) 387

**Vigabatrin**, drug interactions, review (A) 560

**Vinorelbine**, use of inappropriate antidiuretic hormone (CR) 1306

**Vitamins**, antioxidant, endothelial dysfunction (A) 461; bezoars (A) 944

**Wagner, John G.**, obituary (NC) 732

**Warfarin**, interaction, azithromycin (L) 269; azole antifungals (A) 920; fenofibrate (CR) 765; mesalamine (L) 841; ritonavir (CR) 1299

**Wilson's disease**, zinc acetate (A) 78

**Women**, childbearing age, epilepsy (A) 794; folic acid consumption (NC) 624

**Worthing, Dennis B.**, Linwood F. Tice Friend (NC) 280

**Zalcitabine**, with zidovudine, quality of life (RR) 525

**Zaleplon**, insomnia (A) 685

**Zidovudine**, with lamivudine or zalcitabine, quality of life (RR) 525

**Zinc acetate**, adverse reactions, review (A) 83; pharmacokinetics (A) 80; pharmacology (A) 80; Wilson's disease (A) 78

**Zinc lozenges**, common cold (A) 63

**Zolpidem**, insomnia (A) 683

**Zopiclone**, insomnia (A) 685

## AUTHOR INDEX

### A-B

**Abadin, José A.** (author) Probable Diltiazem-Induced Acute Interstitial Nephritis (CR) 656

**Abate, Marie A.** (coauthor) see **Farid, Parnaz**, 1362

**Abdel-Rahman, Susan M.** (coauthor) see **Preston, Stacey L.**, 1231

**Abdo, Ayman** (coauthor) see **Wai, Amy O.**, 1160

**Adick, Victoria O.** (coauthor) see **Nobili, Alessandro**, 120

**Adcock, Kim G.** (author) Pemoline Therapy Resulting in Liver Transplantation (CR) 422

**Al-Tawfiq, Jaffar A.** (coauthor) see **Sorensen, Suellyn J.**, 1020

**Alao, Adekola O.** (author) Isoniazid-Induced Psychosis (CR) 889

**Altundag, M. Kadri** (author) False-Positive Urine Melanin Pigment Reaction Caused by Rifampin (L) 610

**Amodio-Groton, Maria I.** (coauthor) see **Bakog, Denise L.**, 446



Amsden, Guy W (coauthor) see **Trépanier, Eric F**, 204  
 Anderson, Gail D (author) A Mechanistic Approach to Antiepileptic Drug Interactions (A) 554  
 Anderson, Leigh A (author) Zinc Acetate Treatment in Wilson's Disease (A) 78  
 Andrade, Raúl J (author) Hepatic Injury Associated with Losartan (L) 1371  
 Antonov, Karolina IM (author) Prescription and Nonprescription Analgesic Use in Sweden (IR) 485  
 Ariano, Robert E (coauthor) see **Tkach, Carol L**, 387  
 Armstrong, Deborah K (coauthor) see **Joy, Melanie S**, 362  
 Arumugham, Thangam (coauthor) see **Dimmitt, Dan C**, 39  
 Asch, Kathryn J (author) Interaction Between Fenofibrate and Warfarin (CR) 765  
 Astorh, Jeffrey D (coauthor) see **Ruscini, J Mark**, 1248  
 Azzam, Zaher S (coauthor) see **Rosenbaum, Hanna**, 60  
 Baillie, G Mark (author) Insulin and Coronary Artery Disease: Is Syndrome X the Unifying Hypothesis? (A) 233  
 Baldelli, Franco (coauthor) see **Marroni, Massimo**, 843  
 Balog, Denise L (author) HIV Wasting Syndrome: Treatment Update (A) 446  
 Balafoutou, Luis E (author) Management of a Patient with Atrial Fibrillation and Factor VII Deficiency (L) 1251  
 Barclay, Teresa S (author) Glucosamine (A) 574; (author) Comment: Glucosamine: Selecting Appropriate Study Exclusion Criteria (L) 1371  
 Barista, Ibrahim (coauthor) see **Altundag, M Kadri**, 610  
 Barjhoux, Claude E (coauthor) see **Piquet, Catherine Y**, 653  
 Barner, Erica L (author) Donepezil Use in Alzheimer Disease (A) 70  
 Beeson, Michael S (coauthor) see **Gaffney, Pamela N**, 1249  
 Begle, Robert (coauthor) see **Smythe, Maureen A**, 294  
 Beijnen, Jon H (coauthor) see **Oostwegel, Lonneke MM**, 1023  
 Bell, Dawn M (author) Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases (A) 459  
 Ben-Ami, Dan (author) Cutaneous Ulceration: An Unusual Sign of Methotrexate Toxicity — First Report in a Patient Without Psoriasis (CR) 651  
 Ben-Arie, Yehudith (coauthor) see **Rosenbaum, Hanna**, 60  
 Ben-Menachem, Tamir (coauthor) see **Devlin, John W**, 869  
 Bennahou, David A (coauthor) see **Dodd, Melanie A**, 887  
 Bennett, Dean A, Jr (author) Neuropharmacology of St John's Wort (*Hypericum*) (A) 1201  
 Berg, Mary J (coauthor) see **Lewis, Dale P**, 802, 947, 1087  
 Beringer, Paul M (author) Predictive Performance of a Vancomycin-Aminoglycoside Population Model (RR) 176  
 Bermejo, Teresa (coauthor) see **Puente, Marta**, 1369  
 Berning, Shaun E (coauthor) see **Pelquin, Charles A**, 268  
 Bezchlibnyk-Butler, Kalyana (coauthor) see **Ly, Joseph**, 1372  
 Bhattacharya, Vinod S (author) Serotonin Syndrome Induced by Venlafaxine and Fluoxetine: A Case Study in Polypharmacy and Potential Pharmacodynamic and Pharmacokinetic Mechanisms (CR) 432  
 Billington, Charles J (coauthor) see **Filice, Gregory A**, 1158  
 Billups, Sarah J (author) Mifepradil Withdrawn from the Market (L) 841; (author) Mifepradil: A New Class of Calcium-Channel Antagonists (A) 659  
 Bingefors, Kerstin (author) Concomitant Prescribing of Tranquilizers and Hypnotics Among Patients Receiving Antidepressant Prescriptions (RR) 531  
 Bishara, Jihad (coauthor) see **Dux, Shlomo**, 134  
 Bizjak, Eric D (author) Thrombolytic Therapy: A Review of Its Use in Acute Myocardial Infarction (A) 769  
 Bjornson, Darrel C (coauthor) see **Laumann, Julie M**, 1290  
 Blanchet, Patricia (coauthor) see **Navarre-Bellassen, Caroline**, 505  
 Blayac, Jean-Pierre (coauthor) see **Navarre-Bellassen, Caroline**, 505  
 Blum, Ilana (coauthor) see **Dux, Shlomo**, 134  
 Boike, Steven C (coauthor) see **Tenero, David M**, 304  
 Boudreaux, Stanley K (coauthor) see **Anderson, Leigh A**, 78  
 Bourke, Dianne (author) Possible Association between Donepezil and Worsening Parkinson's Disease (L) 610  
 Boyce, Eric G (coauthor) see **Spiller, Sarah A**, 1275  
 Boyd, Ian W (author) Comment: Hyponatremia with Venlafaxine (L) 981  
 Boyle, Duane A (coauthor) see **Tenero, David M**, 304  
 Boyne, Michael (coauthor) see **Raggi, Paolo**, 1141  
 Bradford, Greg S (author) Comment: Modification of Weight-Based Heparin Nomogram (L) 715  
 Bradley, Lee Ann (author) Authors' Reply: Could Acetaminophen Have Played a Role in a Possible Azithromycin-Warfarin Interaction? (L) 844; (coauthor) see **Woldtvedt, Brent R**, 269  
 Bradley, Carole A (coauthor) see **Mittmann, Nicole**, 1244  
 Briceland, Laurie L (coauthor) see **Griswold, Maria W**, 475  
 Brody, Kathleen K (coauthor) see **Ried, L Douglas**, 699  
 Bromfield, Edward B (coauthor) see **Silvestri, Rosalia C**, 1147  
 Brophy, Donald F (coauthor) see **Crouch, Michael A**, 386  
 Brown, Candace S (coauthor) see **Woodrum, Sharon T**, 1209  
 Brown, Leigh Anne (author) Role of Propofol in Refractory Status Epilepticus (A) 1053  
 Brown, Susan L (coauthor) see **Melbourne, Kathleen M**, 1108  
 Brown, Yvonne L (coauthor) see **Shaffer, Christopher L**, 482  
 Brushwood, David B (coauthor) see **Nau, David P**, 642  
 Buck, Marcia L (author) Providing Patients with Written Medication Information (A) 962  
 Buckley, Peter F (author) Novel Antipsychotics and Patient Care in State Hospitals (A) 906

Burlingame, Mark B (author) book review (B) 137  
 Burri, Haran (coauthor) see **Wicki, Jacques**, 892  
 Burt, Melinda S (coauthor) see **Scott-Lennox, Jane A**, 525  
 Bush, Barbara A (coauthor) see **Radomski, Kristine M**, 170  
 Butts, John D (coauthor) see **Faris, Melissa A**, 564  
  
**C-D**  
 Cahoon, Carla L (coauthor) see **Bradley, Lee Ann**, 844; (coauthor) see **Woldtvedt, Brent R**, 269  
 Cami, Jordi (coauthor) see **Mas, Marta**, 980  
 Cammisuli, Salvatore (coauthor) see **Jeffries, J Joel**, 134  
 Campbell, Lance K (coauthor) see **Johnson, Michael D**, 337  
 Campbell, R Keith (author) Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus (A) 1044; (coauthor) see **Johnson, Michael Dean**, 337  
 Carauzi, Daniel H (coauthor) see **Valencia, Mabel E**, 506  
 Carleton, Bruce C (coauthor) see **Eminan, Mahyar**, 1193  
 Carr, Alison M (coauthor) see **Tenero, David M**, 304  
 Carr, Roxane R (author) Primary Induction with Mycophenolate Mofetil and Corticosteroids in a Liver Transplant Recipient with Hepatorenal Syndrome (CR) 45  
 Carter, Barry L (coauthor) see **Billups, Sarah J**, 659, 841  
 Castella, A (coauthor) see **Martinez Perez-Balsa, A**, 1250  
 Castillon, José Luis P (coauthor) see **Porrás, Miguel C**, 185  
 Castle, Sharon S (coauthor) see **Taylor, James R**, 940  
 Cates, Marshall E (author) Concomitant Rash and Blood Dyscrasias in Geriatric Psychiatry Patients Treated with Carbamazepine (CR) 884  
 Celani, Laura (coauthor) see **Nobili, Alessandro**, 120  
 Cersosimo, Robert J (author) Irinotecan: A New Antineoplastic Agent for the Management of Colorectal Cancer (A) 1324; (author) Topotecan: A New Topoisomerase I Inhibiting Antineoplastic Agent (A) 1334  
 Cerulli, Jennifer (author) Chromium Picolinate Toxicity (CR) 428; (author) Update on the Pharmacotherapy of Obesity (A) 88  
 Cerveny, Joli D (author) Issues Surrounding Tight Glycemic Control in People with Type 2 Diabetes Mellitus (A) 896  
 Chang, Ku-Lang (coauthor) see **Smith, Jerry D**, 196  
 Chang, Shu-Ing (author) Pharmacotherapeutic Issues for Women of Childbearing Age with Epilepsy (A) 794  
 Charland, Scott L (author) Low Molecular-Weight Heparins in the Treatment of Pulmonary Embolism (A) 258; (coauthor) see **Spiller, Sarah A**, 1275  
 Chen, Jolie D (author) Extravasation Injury Associated with Low-Dose Dopamine (CR) 545  
 Cheng, Judy WM (author) Infection and Atherosclerosis — Focus on Cytomegalovirus and *Chlamydia pneumoniae* (A) 1310  
 Chowdhry, Tanvir K (coauthor) see **Dreger, Lisa M**, 267  
 Chuck, Susan K (coauthor) see **Martin, Steven J**, 320  
 Chung, Cecilia W (coauthor) see **Carr, Roxane R**, 45  
 Claesson, Stephen B (coauthor) see **Schmidt, Ingrid K**, 27  
 Coast-Senior, Elizabeth A (author) Management of Patients with Type 2 Diabetes by Pharmacists in Primary Care Clinics (RR) 636  
 Connors, John E (coauthor) see **Spiller, Sarah A**, 1275  
 Constance, Thomas D (author) book review (B) 721  
 Cooll, Bruce (coauthor) see **Raggi, Paolo**, 1141  
 Cook, Donna E (author) Successful Desensitization to Dapsone for *Pneumocystis carinii* Prophylaxis in an HIV-Positive Patient, 1302; (coauthor) see **Gidai, Barry E**, 405  
 Coplin, William M (coauthor) see **Murray, Kellie R**, 256  
 Coplu, Lutfu (coauthor) see **Yildiz, Bulent O**, 842  
 Corte, Giuseppe Dalla (coauthor) see **Sessai, Paolo**, 1370  
 Cousins, Elizabeth S (coauthor) see **Knoell, Karen R**, 1299  
 Cramer, Michael B (coauthor) see **Dimmitt, Dan C**, 39  
 Cropp, Cheryl D (coauthor) see **Finnell, Deanna L**, 417  
 Crouch, Michael A (author) Nonsteroidal Antiinflammatory Drug-Induced Hepatitis (VO) 386; (coauthor) see **Ling, Con Ann**, 837  
 Crumrine, Patricia K (coauthor) see **Howrie, Denise L**, 384  
 Csako, Gyorgy A (coauthor) see **Wright, Letitia J**, 508  
 Cupp, Melanie Johns (author) Authors' Reply: Use and Abuse of Flunitrazepam (L) 981; (author) Doxorubicin Dosage Guidelines in a Patient with Hyperbilirubinemia of Gilbert's Syndrome (CR) 1026; (coauthor) see **Simmons, Melissa M**, 117  
 Cushing, Herbert E (coauthor) see **Sorensen, Suellyn J**, 1020  
 Cutler, Neal R (coauthor) see **Frackiewicz-Kozioł, Edyta J**, 132  
 da Camara, Carlos C (author) Glucosamine Sulfate for Osteoarthritis (A) 580  
 Dall, Lawrence H (coauthor) see **Freeman, Collin D**, 1004  
 Dahl, Naomi V (author) Pharmacokinetics of Intraperitoneal Fluconazole During Continuous Cycling Peritoneal Dialysis (RR) 1284  
 Danel, Vincent C (coauthor) see **Piquet, Catherine Y**, 653  
 Dasta, Joseph F (coauthor) see **Woffe, Thomas A**, 1109  
 Davey, Andrew M (coauthor) see **Shaffer, Christopher L**, 482  
 David, Michael (coauthor) see **Ben-Ami, Dan**, 651  
 Davis, Diane D (author) Ambulatory Management of Chemotherapy-Induced Fever and Neutropenia in Adult Cancer Patients (A) 1317  
 Davis, George A (coauthor) see **Ensom, Mary HH**, 1109; (coauthor) see **Finnell, Deanna L**, 417  
 Davis, Steven M (coauthor) see **Lucas, Kristy Holmes**, 970

Davis, Timothy ME (author) Adverse Effects of Antimalarial Prophylactic Drugs: An Important Consideration in the Risk-Benefit Equation (O) 1104  
 Daya, Mohammad (coauthor) see **Himstreet, Julianne E**, 267  
 de Arce, A (coauthor) see **Martinez Perez-Balsa, Agustín**, 1250  
 De Juana, Paloma (coauthor) see **Puente, Marta**, 1369  
 Dellinger, Tracy M (author) Aspirin Burn of the Oral Cavity (VO) 1107; (coauthor) see **Livingston, Harold Mark**, 607  
 Desmeules, Jules (coauthor) see **Wicki, Jacques**, 892  
 Devlin, John William (author) Stress Ulcer Prophylaxis in Medical ICU Patients: Annual Utilization in Relation to the Incidence of Endoscopically Proven Stress Ulceration (RR) 869  
 Diaz, Philip R (coauthor) see **Meadowcroft, Amy M**, 309  
 Dice, James E (coauthor) see **Venkatarangan, Raman**, 755  
 Dickson, Natalie (coauthor) see **Raggi, Paolo**, 1141  
 Didur, Cathy D (coauthor) see **Grymponre, Ruby E**, 749  
 Dimmitt, Dan C (author) Effect of Infusion Rate on the Pharmacokinetics and Tolerance of Intravenous Dolasetron Mesylate (RR) 39  
 DiNunzio, Lucio (coauthor) see **Herrington, Jon D**, 611  
 Dodd, Melanie A (author) Minocycline-Associated Tooth Staining (CR) 887  
 Dole, Ernest J (coauthor) see **Dodd, Melanie A**, 887  
 Donnelly, Ronald F (coauthor) see **Thompson, Robert L**, 739  
 Dowless, Gregory V (coauthor) see **da Camara, Carlos C**, 580  
 Dreger, Lisa M (author) Intermittent-Dose Metronidazole-Induced Peripheral Neuropathy (L) 267  
 Druckenbrod, Richard W (coauthor) see **Bourke, Dianne**, 610  
 Dunlap, Donna S (coauthor) see **Lenz, Kristi L**, 316  
 Durán Q, Jose A (coauthor) see **Abadín, Jose A**, 656  
 Dux, Shlomo (author) Medroxyprogesterone Acetate-Induced Secondary Adrenal Insufficiency (L) 134

## E-G

Einarson, Thomas R (coauthor) see **Kennie, Natalie R**, 17; (coauthor) see **Mittmann, Nicole**, 1244  
 Ensom, Mary HH (author) Authors' Reply: Validation of the Hartford Nomogram in Trauma Surgery Patients (L) 1109; (coauthor) see **Finnell, Deanna L**, 417; (coauthor) see **Radomski, Kristine M**, 170  
 Epstein, Marcia E (coauthor) see **Balog, Denise L**, 446  
 Ercan-Fang, Naciye (coauthor) see **Filice, Gregory A**, 1158  
 Ernst, Michael E (author) Acyclovir- and Ganciclovir-Induced Neurotoxicity (A) 111; (author) Oral Corticosteroids for Pain Associated with Herpes Zoster (A) 1099  
 Erramoupe, John (author) Authors' Reply: Effect on Dissolution from Halving Methylphenidate Extended-Release Tablets (L) 1372  
 Esmail, Zahra N (author) Losartan as an Alternative to ACE Inhibitors in Patients with Renal Dysfunction (A) 1096  
 Espindola, Jorge H (coauthor) see **Valencia, Mabel E**, 506  
 Essex, Margaret A Noyes (author) book review (B) 986  
 Etninan, Mahyar (author) Evidence-Based Pharmacotherapy: Review of Basic Concepts and Applications in Clinical Practice (A) 1193  
 Ette, Ene I (author) Statistical Graphics in Pharmacokinetics and Pharmacodynamics: A Tutorial (A) 818  
 Fan-Havard, Patty (coauthor) see **Kendle, Julie B**, 1181  
 Farid, Parnaz (author) Buspirone Use for Smoking Cessation (A) 1362  
 Farina, Marieluiza (coauthor) see **Nobili, Alessandro**, 120  
 Faris, Melissa A (author) Treatment and Prophylaxis of Disseminated *Mycobacterium avium* Complex in HIV-Infected Individuals (A) 564  
 Farré, Magi (coauthor) see **Mas, Marta**, 980  
 Farrington, Elizabeth A (coauthor) see **Adcock, Kim G**, 422  
 Fassett, William E (author) book review (B) 987  
 Fein, Jacqueline L (coauthor) see **Dahl, Naomi V**, 1284  
 Ferreira, Ema (author) Desmopressin for Nocturia and Enuresis Associated with Multiple Sclerosis (A) 1114  
 Fiechter, Helen B (coauthor) see **Sitzman, Scott J**, 973  
 Fierro, Lesley (coauthor) see **Fraser, Charles G**, 1111  
 Filice, Gregory A (author) Neuroleptic Malignant Syndrome Associated with Olanzapine (CR) 1158  
 Finnell, Deanna L (author) Validation of the Hartford Nomogram in Trauma Surgery Patients (RR) 417; (coauthor) see **Ensom, Mary HH**, 1109  
 Fogel, Ronald P (coauthor) see **Devlin, John W**, 869  
 Fong, Nancy T (coauthor) see **Yee, Helen S**, 1030  
 Foote, Edward F (coauthor) see **Dahl, Naomi V**, 1284  
 Fox, Janet L (coauthor) see **Prince, Randall A**, 875  
 Frackiewicz-Kozioł, Edyta J (author) Potential for Adverse Events in Patients with Generalized Anxiety Disorder (L) 132  
 Franey, Rodney J (coauthor) see **Ernst, Michael E**, 111  
 Fraser, Charles G (author) Comment: Troglitazone (L) 1111  
 Freeman, Collin D (author) Relative Bioavailability of Atovaquone Suspension when Administered with an Enteral Nutrition Supplement (RR) 1004  
 Frey, Otto R (author) Comparison of Phenytoin Serum Concentrations in Premature Neonates Following Intravenous and Oral Administration (RR) 300  
 Frighetto, Luciana (coauthor) see **Zed, Peter J**, 536  
 Frye, Carla B (author) Using Literature in Health Care: Reflections on "The Yellow Wallpaper" (A) 829

Fujimura, Yasuo (coauthor) see Kusumoto, Masaaki, 182  
 Fung, John (coauthor) see Murray, Michelle, 633  
 Gaburri, Manuela (coauthor) see Marroni, Massimo, 843  
 Gaffney, Pamela N (author) Nefazodone Overdose (L) 1249  
 Gal, Peter (coauthor) see Shaffer, Christopher L., 482  
 Garcia, Benito (coauthor) see Puente, Maria, 1369  
 Gardner, David M (author) Sumatriptan Contraindications and the Serotonin Syndrome (CR) 33  
 Garey, Kevin W (author) Azathioprine Hypersensitivity Reaction in a Patient with Ulcerative Colitis (CR) 425  
 Garland, Michelle L (author) The Role of Zinc Lozenges in Treatment of the Common Cold (A) 63  
 Garrett, Clifford A (author) Syndrome of Inappropriate Antidiuretic Hormone Associated with Vinorelbine Therapy (CR) 1306  
 Garvey, Michael J (author) Advantages of Repackaging Ketorolac Tromethamine Syringes (L) 1252  
 Gauthier, Isabelle (coauthor) see Cerulli, Jennifer, 428  
 Gaurava, Scott R (author) Leukocytoclastic Vasculitis Associated with Clarithromycin (CR) 543  
 Gazzuolo, Debra J (coauthor) see Dreger, Lisa M., 267  
 Gebu, Freweini (coauthor) see Nobili, Alessandro, 1280  
 Gerber, Patricia E (author) Selective Serotonin-Reuptake Inhibitor-Induced Movement Disorders (A) 692  
 Gever, Larry N (author) Correction: The Role of the Ketogenic Diet in Children with Intractable Seizures (L) 1373  
 Giannetti, Vincent J (coauthor) see Schlicht, John R., 129  
 Gidal, Barry E (author) Gabapentin Absorption: Effect of Mixing with Foods of Varying Macronutrient Composition (RR) 405; (coauthor) see Graves, Nina M., 1239  
 Gil, Maria-Esperanza (author) Treatment of Extravasation of Parenteral Nutrition Solution (CR) 51  
 Gilbert, Deward L (coauthor) see Trissel, Lawrence A., 1013  
 Gilliam, Frank G (coauthor) see Graves, Nina M., 1239  
 Gleason, Patrick P (coauthor) see Dreger, Lisa M., 267  
 Goebel, Shelly Reed (coauthor) see Wilhite, Shannon L., 834  
 Goldfarb, Stanley (coauthor) see Spinler, Sarah A., 1275  
 Golub, Jonathan E (coauthor) see Perl, Trish M., 57  
 Gordon, Richard L (author) Prolonged Central Intravenous Ketorolac Continuous Infusion in a Cancer Patient with Intractable Bone Pain (CR) 193  
 Gottwald, Mildred D (author) book review, 1374  
 Gowan, Debra J (coauthor) see Thompson, Robert L., 739  
 Grabe, Darren W (coauthor) see Cerulli, Jennifer, 428  
 Grabenstein, John D (author) Should Vaccines Require a Prescription? (O) 495  
 Graham, Antonette (coauthor) see Dimmitt, Dan C., 39  
 Graves, Nina M (author) The New Generation of Antiepileptic Drugs: Unresolved Questions (E) 1239  
 Gray, Shelly L (coauthor) see Barner, Erica L., 70  
 Gray, Vanessa Seals (author) Syncopal Episodes Associated with Cisapride and Concurrent Drugs (CR) 648  
 Griswold, Maria W (author) Is Amphotericin B Test Dosing Needed? (A) 475  
 Grogan, Tracy A (coauthor) see Murray, Michelle, 633  
 Groves, Scott (author) Comment: Validation of the Hartford Nomogram in Trauma Surgery Patients (L) 1108  
 Grymonpre, Ruby E (author) Pill Count, Self-Report, and Pharmacy Claims Data to Measure Medication Adherence in the Elderly (RR) 749; (author) The Medication Information Line for the Elderly: An 8-Year Cumulative Analysis (RR) 743  
 Gums, John G (coauthor) see Smith, Jerry D., 196  
 Gupta, Aditya K (author) Heparin-Induced Thrombocytopenia (CR) 55

## H-K

Habowski, Suzette R (author) book review, 1374  
 Hagmeyer, Kathleen O (coauthor) see Garland, Michelle L., 63  
 Hahne, William (coauthor) see Dimmitt, Dan C., 39  
 Hakejari, Sara L (coauthor) see Anderson, Leigh A., 78  
 Halperin, Jerome A (author) Useful Patient Information on Prescription Drugs (L) 612  
 Halperin, John J (author) book review (B) 1256  
 Haznedaroglu, Ibrahim C (coauthor) see Yildiz, Bulent O., 842  
 Healy, Daniel P (author) Correction: Reduced Tetracycline Bioavailability Caused by Magnesium Aluminum Silicate in Liquid Formulations of Bismuth Subsalicylate (L) 506  
 Hempel, Alan G (author) Pharmacoeconomic Analysis of Using Sinemet CR over Standard Sinemet in Parkinsonian Patients with Motor Fluctuations (RR) 878  
 Hening, Wayne A (coauthor) see Wagner, Judy G., 680  
 Herrington, Jon D (author) Lack of CNS Penetration of Docetaxel in a Patient with Leptomeningeal Carcinomatosis (L) 611  
 Heyneman, Catherine A (author) Glucosamine for Osteoarthritis: Cure or Conundrum? (E) 602  
 Higa, Gerald M (coauthor) see Cupp, Melanie Johns, 1026  
 Hillaire-Buys, Dominique (coauthor) see Navarre-Belhasen, Caroline, 505  
 Himstreet, Julianne E (author) Hypotension and Orthostasis Following a Risperidone Overdose (L) 267  
 Hoar, Marion E (author) Comment: Cost-Effective Pharmacological Care for HIV Disease (L) 716  
 Hodak, Emmilia (coauthor) see Ben-Ami, Dan, 651  
 Holdman, Mark (coauthor) see Garvey, Michael J., 1252  
 Hopper, Roy L (coauthor) see Faris, Melissa A., 564

Hori, Shigeaki (coauthor) see Morikawa, Norifumi, 269, 1008  
 Howard, Patricia A (author) book review (B) 137  
 Howrie, Denise L (author) The Ketogenic Diet: The Need for a Multidisciplinary Approach (E) 384  
 Huitt, Gwen A (coauthor) see Pelouquin, Charles A., 268  
 Hunt, Thomas L (coauthor) see Dimmitt, Dan C., 39  
 Hunter, Dee A (coauthor) see Thompson, Gwendolyn H., 1067  
 Irlin, Bernard E (coauthor) see Tenero, David M., 304  
 Irtel von Brendorff, Alexis (coauthor) see Frey, Otto R., 300  
 Isacson, Dag GL (coauthor) see Antonov, Karolina IM, 485; (coauthor) see Bingefer, Kerstin, 531  
 Iseman, Michael D (coauthor) see Pelouquin, Charles A., 268  
 Iskadjian, Michael (coauthor) see Mittmann, Nicole, 1244  
 Jackson, Cherry Wyant (author) book review (B) 1255  
 Jarvi, Eric J (coauthor) see Erramoupe, John, 1372  
 Jeffries, J Joel (author) Psychosis Secondary to Long-Term Levamisole Therapy (L) 134  
 Johns, Thomas E (coauthor) see Bell, Dawn M., 459  
 Johnson, Michael D (author) Trogliatone: Review and Assessment of Its Role in the Treatment of Patients with Impaired Glucose Tolerance and Diabetes Mellitus (A) 337; (coauthor) see Setter, Stephen M., 264  
 Johnson, Richard E (coauthor) see Ried, L Douglas, 699  
 Jorkasky, Diane K (coauthor) see Tenero, David M., 304  
 Joy, Melanie S (author) A Primer on Continuous Renal Replacement Therapy for Critically Ill Patients (A) 362  
 Jung, Rose (coauthor) see Martin, Steven J., 320  
 Kameda, Takaya (coauthor) see Kusumoto, Masaaki, 182  
 Kaplan-Machlis, Barbara (author) book review (B) 846  
 Kapaian, Toros (coauthor) see Dahl, Naomi V., 1284  
 Karki, Shyam D (author) Authors' Reply: Hyponatremia with Venlafaxine (L) 981; (coauthor) see Masood, Gule Rana, 49  
 Katona, Brian G (coauthor) see Walters, J Ken, 478  
 Katal, Neelam (coauthor) see Howrie, Denise L., 384  
 Katz, Roger C (coauthor) see Kehoe, William A., 1076  
 Kawashima, Hisanori (coauthor) see Morikawa, Norifumi, 1008  
 Kehoe, William A (author) Health Behaviors and Pharmacotherapy (A) 1076  
 Kelley, Catherine L (coauthor) see Coast-Senior, Elizabeth A., 636  
 Kelly, H William (author) Comparison of Inhaled Corticosteroids (A) 220  
 Kendle, Julie B (author) Cidofovir in the Treatment of Cytomegalovirus Disease (A) 1181  
 Kendrick, Michael G (coauthor) see Neal, Casey Powe, 376  
 Kennie, Natalie R (author) Critical Analysis of the Pharmaceutical Care Research Literature (RR) 17  
 Khoshbin, Shahram (coauthor) see Silvestri, Rosalia C., 1147  
 Kintzel, Polly E (author) Correction: Symptomatic Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Azithromycin (L) 388  
 Kita, Mariko (coauthor) see Stecker, Mark M., 1168  
 Klaassen, Spencer L (author) Ticlopidine-Induced Phenytoin Toxicity (CR) 1295  
 Klepser, Michael E (author) Therapy of *Candida* Infections: Susceptibility Testing, Resistance, and Therapeutic Options (A) 1353  
 Klepser, Teresa B (coauthor) see Ernst, Michael E., 1099  
 Kliner, Dawn EJ (coauthor) see Charland, Scott L., 258  
 Klutman, Neil E (coauthor) see Freeman, Collin D., 1004  
 Knoell, Daren L (author) Clinical Aspects of Gene Therapy (O) 977  
 Knoell, Karen R (author) Potential Interaction Involving Warfarin and Ritonavir (CR) 1299  
 Knowles, Sandra R (coauthor) see Park, Hayley, 1249; (coauthor) see Phillips, Elizabeth J., 843  
 Kossey, Joyce L (coauthor) see Cook, Donna E., 1302  
 Kovacs, Michael J (coauthor) see Gupta, Aditya K., 55  
 Kowalski, Jonathan W (coauthor) see Gidal, Barry E., 405  
 Kozyskyj, Anita L (author) Validation of an Electronic, Population-Based Prescription Database (RR) 1152  
 Kraisinger, Marijo (coauthor) see Howrie, Denise L., 384  
 Kraus, Donna M (author) book review (B) 1116  
 Krivoy, Norberto (coauthor) see Rosenbaum, Hanna, 60  
 Kroner, Beverly A (coauthor) see Coast-Senior, Elizabeth A., 636  
 Kropff, Marci A (coauthor) see Lamsam, Grace D., 409  
 Kusumoto, Masaaki (author) Lack of Pharmacokinetic Interaction Between Mexiletine and Omeprazole (RR) 182  
 Kuyumjian, Jirair (coauthor) see Mallet, Louise, 201

## L-M

Lal, Avtar (author) Information Contents of Drug Advertisements: An Indian Experience (IR) 1234  
 Lamp, Kenneth C (coauthor) see Freeman, Collin D., 1004  
 Lamsam, Grace D (author) Community Pharmacists' Assessments and Recommendations for Treatment in Four Case Scenarios (RR) 409  
 Latham, Georgia S (coauthor) see Meadowcroft, Amy M., 309  
 Laumann, Julie M (author) Treatment of Medicaid Patients with Asthma: Comparison with Treatment Guidelines Using Disease-Based Drug Utilization Review Methodology (RR) 1290  
 Leaf, Emily V (author) Comment: Venlafaxine Overdose and Seizure (L) 135

Lecumberri, José N (coauthor) see Porras, Miguel C., 185  
 Leder, Rachel D (coauthor) see Cerveny, Joli D., 896  
 Leeder, J Steven (author) book review (B) 986  
 Lemoigne, Aude H (coauthor) see Piquet, Catherine V., 653  
 Lenz, Kristi L (author) Continuous Fentanyl Infusion: Use in Severe Cancer Pain (CR) 316  
 Leo, Raphael J (author) Movement Disturbances Associated with the Use of Selective Serotonin-Reuptake Inhibitors (O) 712  
 Lerner, Stephen A (coauthor) see Slavik, Richard S., 189  
 Letwin, Shallen R (coauthor) see Ferreira, Ema, 114  
 Lever, Jacqueline (coauthor) see Murray, Michelle, 633  
 Levin, Gary M (coauthor) see Brown, Leigh Anne, 1053  
 Lewis, Dale P (author) Drug and Environmental Factors Associated with Adverse Pregnancy Outcomes Part I: Antiepileptic Drugs, Contraceptives, Smoking, and Folate (A) 802; (author) Drug and Environmental Factors Associated with Adverse Pregnancy Outcomes Part II: Improvement with Folic Acid (A) 947; (author) Drug and Environmental Factors Associated with Adverse Pregnancy Outcomes Part III: Folic Acid: Pharmacology, Therapeutic Recommendations, and Economics (A) 1087  
 Lewis, Russell E (coauthor) see Klepser, Michael E., 1353  
 Ling, Con Ann (author) Theophylline for Chronic Symptomatic Bradycardia in the Elderly (A) 837  
 Liu, Barbara A (coauthor) see Phillips, Elizabeth J., 843  
 Livingston, H Mark (author) Intrinsic Staining of Teeth Secondary to Tetracycline (VO) 607; (coauthor) see Dellinger, Tracy M., 1107  
 Lo, Agnes MS (coauthor) see Wai, Amy O., 1160  
 Loewen, Peter S (coauthor) see Esmail, Zahra N., 1096  
 Loeza, Ben M (author) Update on Drug Interactions with Azole Antifungal Agents (A) 915; (coauthor) see Cerulli, Jennifer, 428  
 Lopez, Larry M (coauthor) see Bell, Dawn M., 459  
 López, P (coauthor) see Martínez Pérez-Balsa, A., 1250  
 López de Munain, A (coauthor) see Martínez Pérez-Balsa, A., 1250  
 Lucarotti, Richard L (coauthor) see Smythe, Maureen A., 294  
 Lucas, Dirk S (coauthor) see Prince, Randall A., 115  
 Lucas, Kristy Holmes (author) Calcium in Corticosteroid-Induced Osteoporosis (A) 970  
 Lucena, M Isabel (coauthor) see Andrade, Raul J., 1371  
 Luedtke, Sherry A (author) book review (B) 1115  
 Luer, Mark S (author) Tiagabine: A Novel Antiepileptic Drug (A) 1173  
 Lundberg, David E (coauthor) see Tenero, David M., 304  
 Ly, Joseph (author) Comment: Effect on Dissolution from Halving Methylphenidate Extended-Release Tablets (L) 1372  
 Lynd, Larry D (coauthor) see Gardner, David M., 33; (coauthor) see Gerber, Patricia E., 692  
 Maaty, Mohamed A (coauthor) see Hempel, Alan G., 878  
 Macario, Gianluca (coauthor) see Nobili, Alessandro, 1280  
 MacElroy, Dawn E (coauthor) see Adcock, Kim G., 422  
 MacLaren, Robert (author) Respiratory Failure Following Oral Administration of Metoclopramide (CR) 1017  
 Magnus, Ryan D (coauthor) see Bhatara, Vinod S., 432  
 Malgor, Luis A (coauthor) see Valsencia, Mabel E., 506  
 Mallaret, Michel P (coauthor) see Piquet, Catherine V., 653  
 Mallory, Laurie (coauthor) see Rojas-Fernandez, Carlos, 980  
 Mallet, Louise (author) Indomethacin-Induced Behavioral Changes in an Elderly Patient with Dementia (CR) 201  
 Malone, Margaret (coauthor) see Cerulli, Jennifer, 428  
 Maloney, Melissa M (coauthor) see Gidal, Barry E., 405  
 Mareni, Roberto (coauthor) see Sossai, Paolo, 1370  
 Marinella, Mark A (author) Mesalamine and Warfarin Therapy Resulting in Decreased Warfarin Effect (L) 841  
 Marom, Daphna (coauthor) see Dux, Shlomo, 134  
 Marra, Carlo A (coauthor) see Zed, Peter J., 536  
 Marra, Fawziah (coauthor) see Wai, Amy O., 1160  
 Marroni, Massimo (author) Acute Interstitial Nephritis Secondary to the Administration of Indinavir (L) 843  
 Marti Massó, JF (coauthor) see Martínez Pérez-Balsa, A., 1250  
 Martin, David E (coauthor) see Tenero, David M., 304  
 Martin, Steven J (author) Levofloxacin and Sparfloxacin: New Quinolone Antibiotics (A) 320  
 Martineau, Pierre (author) Low-Molecular-Weight Heparins in the Treatment of Deep-Vein Thrombosis (A) 588  
 Martínez Pérez-Balsa, A (author) Hepatotoxicity Due to Ticlopidine (L) 1250  
 Marx, Michael A (coauthor) see Joy, Melanie S., 362  
 Mas, Marta (author) Comment: Use and Abuse of Flunitrazepam (L) 980  
 Mashimo, Kohji (coauthor) see Kusumoto, Masaaki, 182  
 Masood, Gule Rana (author) Hyponatremia with Venlafaxine (CR) 49; (coauthor) see Karki, Shyam D., 981  
 Mateu, Javier (coauthor) see Gil, Maria-Esperanza, 51  
 Matsuzewski, Karl A (coauthor) see Windisch, Paul A., 437  
 Matzinger, Frederick RK (coauthor) see Thompson, Robert L., 739  
 Matzke, Gary R (coauthor) see Joy, Melanie S., 362  
 Mauro, Vincent F (coauthor) see Bizjak, Eric D., 769  
 May, D Byron (coauthor) see Terra, Steven G., 1111  
 McAuley, James W (coauthor) see Chang, Shu-Ing, 794  
 McCarty, Gary M (coauthor) see Barclay, Teresa S., 574, 1371  
 McCarthy, Michelle W (coauthor) see Ward, Kristina E., 549  
 McCloskey, William W (coauthor) see Rose, Eric W., 381  
 McCombs, Jacqueline R (coauthor) see Venkataraman, Raman, 755

McDougall, Beth C (coauthor) see Filice, Gregory A, 1158  
 McFarland, Benton H (coauthor) see Ried, L Douglas, 699  
 McGhee, H William (coauthor) see Howie, Denise L, 384;  
 (coauthor) see Venkataraman, Raman, 755  
 McGoldrick, M Donald (coauthor) see Cerulli, Jennifer, 428  
 McKinney, Patrick E (coauthor) see McLaughlin, Steven A, 312  
 McLaughlin, Steven A (author) Antacid-Induced Hypermagnesemia in a Patient with Normal Renal Function and Bowel Obstruction (CR) 312  
 McLeod, Richard (author) Comment: Unexpectedly Low Phenytoin Concentration in a Patient Receiving Ciprofloxacin (L) 1110  
 Meadowcroft, Amy M (author) Clostridium difficile Toxin-Induced Colitis After Use of Clindamycin Phosphate Vaginal Cream (CR) 309  
 Mecozzi, Fiorella (coauthor) see Marroni, Massimo, 843  
 Medicus-Bringa, Margaret A (author) book review (B) 1115  
 Meisner, Paul D (author) book review (B) 271  
 Melbourne, Kathleen M (author) Gynecosmia with Stavudine Treatment in an HIV-Positive Patient (L) 1108  
 Melko, George P (coauthor) see Turco, Thomas F, 758  
 Messick, Chad R (coauthor) see Martin, Steven J, 320  
 Messori, Andrea (author) Authors' Reply: Cost-Effective Pharmacological Care for HIV Disease (L) 716  
 Meyer, Joette M (coauthor) see Martin, Steven J, 320  
 Michalets, Elizabeth Landrum (author) Torsade de Pointes Resulting from the Addition of Droperidol to an Existing Cytomegalovirus P450 Drug Interaction (CR) 761  
 Miller, Sarah J (coauthor) see Bradley, Lee Ann, 844; (coauthor) see Woldtvedt, Brent R, 269  
 Mills, Rose J (coauthor) see Scott-Lennox, Jane A, 525  
 Mittmann, Nicole (author) A Proposal for Structured Abstracts of Health Economic Studies (O) 1244  
 Monsanto, Homero A (author) book review (B) 1255  
 Montgomery, Patrick R (coauthor) see Grymonpre, Ruby E, 749  
 Mori, Teruaki (coauthor) see Morikawa, Norifumi, 269, 1008  
 Morikawa, Norifumi (author) Pharmacokinetics of Anticancer Drugs in Cerebrospinal Fluid (RR) 1008; (author) Pharmacokinetics of Pirarubicin in Plasma and Cerebrospinal Fluid (L) 269  
 Mueller, Bruce A (coauthor) see Worland, Melinda A, 1216  
 Mulder, Jan Willem (coauthor) see Oostwegel, Lonneke MM, 1023  
 Muller, Barbara A (coauthor) see Phillips, Beth Bryles, 1165  
 Mungall, Dennis R (coauthor) see Balfordano, Luis E, 1251  
 Murray, Michelle (author) Comparison of Tacrolimus Absorption in Transplant Patients Receiving Continuous Versus Interrupted Enteral Nutritional Feeding (RR) 633  
 Murry, Kellie R (author) Urinary Infection in the Treatment of Intraventricular Hemorrhage (A) 256  
 Mustard, Cameron A (coauthor) see Kozyskyj, Anita L, 1152

## N-R

Nahata, Millip C (author) Troubling Issues with Research Publications (E) 126; (coauthor) see Preston, Stacey L, 1231; (coauthor) see Tallian, Kimberly B, 349  
 Naldi, Luigi (coauthor) see Nobili, Alessandro, 120  
 Nau, David P (author) State Pharmacy Regulators' Opinions on Regulating Pharmaceutical Care Outcomes (RR) 642  
 Navarre-Bellassen, Caroline (author) Multiple Congenital Malformations Associated with Topical Tretinoin (L) 505  
 Nawarskas, James J (coauthor) see Spiller, Sarah A, 103; (coauthor) see Spiller, Sarah A, 1275  
 Neal, Casey Powe (author) Carvedilol Use in Heart Failure (A) 376  
 Nicolis, Enrico (coauthor) see Nobili, Alessandro, 120  
 Nilsson, Lars G (coauthor) see Schmidt, Ingrid K, 27  
 Nobili, Alessandro (author) Doxycycline: A Private Toll-Free Telephone Medical Information Service: Five Years of Activity: Old Problems and New Perspectives (A) 120  
 Nosinowitz, Sidney (coauthor) see Gavara, Scott R, 543  
 O'Shea, Marianne (coauthor) see Chen, Julie L, 545  
 Ogawa, C Dwayne (author) book review (B) 509  
 Oostwegel, Lonneke MM (author) Hepatitis During Chloramphenicol Prophylaxis (CR) 1023  
 Orlando, Patricia L (author) Pressure Ulcer Management in the Geriatric Patient (A) 1221  
 Ottemann, Stuart (author) Comment: Mibefradil, A New Class of Calcium-Channel Antagonists (L) 1372  
 Papathomas, Frank J (author) see Windisch, Paul A, 437  
 Park, Hayley (author) Serum Sickness-Like Reaction to Itraconazole (L) 1249  
 Partovi, Nilufar (coauthor) see Carr, Roxane R, 45  
 Paterson, David L (author) Exacerbated Hyperglycemia Associated with Nefinavir (L) 609  
 Patterson, William R (coauthor) see Karki, Shyam D, 981; (coauthor) see Masood, Gule Rana, 49  
 Paul, K Lynn (coauthor) see Bhattacharya, Vinod S, 432  
 Peak, Amy S (author) Systemic Adverse Effects Associated with Topically Applied Latanoprost (L) 504  
 Pelouquin, Charles A (author) Levofloxacin for Drug-Resistant Mycobacterium tuberculosis (L) 268  
 Pendland, Susan L (coauthor) see Martin, Steven J, 320  
 Pereira, Robert O (coauthor) see Raggi, Paolo, 1141

Pérez de León, José A (coauthor) see Abadín, José A, 656  
 Pert, Trish M (author) New Approaches to Reduce Staphylococcus aureus Nosocomial Infection Rates: Treating S aureus Nasal Carriage (suppl) S7  
 Peters, Michael J (coauthor) see Devlin, John W, 869  
 Pfaffler, Michael A (coauthor) see Klepper, Michael E, 1353  
 Phillips, Beth Bryles (author) Severe Neuromuscular Complications Possibly Associated with Amlodipine (CR) 1165  
 Phillips, Elizabeth J (author) Rapid Onset of Risperidone-Induced Hepatotoxicity (L) 843  
 Phun, Lisa (coauthor) see Bennett, Dean A Jr, 1201  
 Platek, Michelle Ann (coauthor) see Lomaestro, Ben M, 915  
 Piquet, Catherine Y (author) Respiratory Depression Following Administration of Intrathecal Bupivacaine to an Opioid-Dependent Patient (CR) 653  
 Pisupati, Jaya (coauthor) see Venkataraman, Raman, 755  
 Pitlik, Silvio (coauthor) see Dux, Shlomo, 134  
 Pitterle, Michael E (coauthor) see Gidal, Barry E, 405  
 Plaza, Susana (coauthor) see Puente, Marta, 1369  
 Polk, Jeffrey F (coauthor) see Bennett, Dean A Jr, 1201  
 Polk, Ronald E (author) Red Man Syndrome (VO) 840  
 Porras, Miguel C (author) Trimethoprim/Sulfamethoxazole and Metabolic Acidosis in HIV-Infected Patients (CR) 185  
 Porter, William H (author) book review (B) 272  
 Powers, Richard (coauthor) see Cates, Marshall, 884  
 Preskorn, Sheldon H (coauthor) see Bhattacharya, Vinod S, 432  
 Preston, Stacey L (author) Empiric Treatment of Uncomplicated Urinary Tract Infections (A) 1231  
 Prince, Randall A (author) Effect of a Dual-Lumen Peripheral Catheter on the Delivery of Known Incompatible Medications (RR) 875  
 Probst, Wiltrud (coauthor) see Frey, Otto R, 300  
 Pucino, Frank (coauthor) see Wright, Letitia J, 508  
 Puente, Marta (author) Increase in Serum Carbamazepine Concentrations after Acute Viral Hepatitis (L) 1369  
 Pylychuk, George B (author) ACE Inhibitor—Versus Angiotensin II Blocker—Induced Cough and Angioedema (A) 1060  
 Raasch, Ralph H (coauthor) see Faris, Melissa A, 564  
 Radabaugh, Rhonda S (coauthor) see Worland, Melinda A, 1216  
 Radomski, Kristine M (author) Collaboration Between Pharmacy and Laboratory: Defining Total Allowable Error Limits for Therapeutically Monitored Drugs (RR) 170  
 Raebel, Marsha A (coauthor) see Davis, Diane D, 1317  
 Raffi, Robert B (coauthor) see Bennett, Dean A Jr, 1201  
 Raggi, Paolo (author) Influence of Prior ACE Inhibitor Therapy on Morbidity and Mortality Following Acute Myocardial Infarction (RR) 1141  
 Rainish, Michael C (coauthor) see Garey, Kevin W, 425  
 Ramirez, Julio A (author) Switch Therapy with  $\beta$ -Lactam/ $\beta$ -Lactamase Inhibitors in Patients with Community-Acquired Pneumonia (suppl) S22  
 Ransom, J Laurence (coauthor) see Shaffer, Christopher L, 482  
 Rapp, Robert P (author) Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions (A) 785  
 Reed, Michael D (author) Rational Prescribing of Extended-Spectrum Penicillin/ $\beta$ -Lactamase Inhibitor Combinations: Focus on Ticarcillin/Clavulanic Acid (suppl) S17; (author) Symposium Introduction (suppl) S5  
 Rheney, Catherine C (author) Oral Ketoconazole in Cutaneous Fungal Infections (A) 709  
 Rho, Jay P (coauthor) see Beringer, Paul M, 176  
 Rhodes, Richard S (coauthor) see Heyneman, Catherine A, 602  
 Rhoney, Denise H (coauthor) see Luer, Mark S, 1173; (coauthor) see Murry, Kellie R, 256  
 Ried, L Douglas (author)  $\beta$ -Blockers and Depression: The More the Merrier? (A) 699  
 Rinehart, John J (coauthor) see Herrington, Jon D, 611  
 Rivera, Nadya G (coauthor) see Cheng, Judy WM, 1310  
 Robb, Jon L (coauthor) see Sorensen, Suellyn J, 1020  
 Rock, Gail A (coauthor) see Asch, Kathryn J, 765  
 Rojas-Fernandez, Carlos (author) Indomethacin is Inappropriate for Use in the Geriatric Population (L) 980  
 Rose, Eric W (author) Glutathione in Hypersensitivity to Trimethoprim/Sulfamethoxazole in Patients with HIV Infection (A) 381  
 Rosenbaum, Hanna (author) Amiodarone-Associated Granuloma in Bone Marrow (CR) 60  
 Roset, Pere N (coauthor) see Mas, Marta, 980  
 Rossetti, Ave (coauthor) see Nobili, Alessandro, 120  
 Ruibal, M (coauthor) see Martinez Perez-Balsa, A, 1250  
 Ruiz-Martinez, J (coauthor) see Martinez Perez-Balsa, A, 1250  
 Ruscin, J Mark (author) Lingual Lesions Secondary to Prolonged Contact with Saltsate Tablets (VO) 1248  
 Russell, Douglas C (coauthor) see Raggi, Paolo, 1141  
 Rutecki, Paul A (coauthor) see Gidal, Barry E, 405  
 Rutschmann, Olivier T (coauthor) see Wicki, Jacques, 892  
 Rybak, Michael J (coauthor) see Slavik, Richard S, 189

## S-Z

Saddier, Christine M (coauthor) see Rheney, Catherine C, 709

Sage, Jacob I (coauthor) see Hempel, Alan G, 878  
 Santalla, Fermin (coauthor) see Andrade, Raul J, 1371  
 Sanz, Maria José (coauthor) see Puente, Marta, 1369  
 Santee, Jennifer A (coauthor) see Ernst, Michael E, 1099  
 Sarda, Pierre (coauthor) see Navarre-Bellassen, Caroline, 505  
 Sauder, Daniel N (coauthor) see Gupta, Aditya K, 55  
 Schettino, Francesco (coauthor) see Nobili, Alessandro, 120  
 Schlicht, John R (author) Authors' Reply: Modification of Weight-Based Heparin Nomogram (L) 715; (author) Reasons to Question Psychologist Prescribing (O) 129  
 Schmidt, Ingrid K (author) Physician and Staff Assessments of Drug Interventions and Outcomes in Swedish Nursing Homes (RR) 27  
 Schuckman, Hugh A (coauthor) see Gaffney, Pamela, N 1249  
 Schuster, Brenda G (coauthor) see Kennel, Natalie R, 17  
 Schwarzmann, Stephen W (author) Novel Cost-Effective Approaches to the Treatment of Community-Acquired Infections (suppl) S27  
 Scoggins, J Allen (coauthor) see Willhite, Shannon L, 834  
 Scott-Lennox, Jane A (author) Impact of Zidovudine Plus Lamivudine or Zalcitabine on Health-Related Quality of Life (RR) 525  
 Searson, Kathleen M (coauthor) see Dahl, Naomi V, 1284  
 Segars, Larry W (author) book review (B) 508  
 Setter, Stephen M (author) Transdermal Nicotine Replacement Smoking Cessation Therapy (A) 264  
 Shaffer, Christopher L (author) Ampicillin-Induced Neurotoxicity in Very-Low-Birth-Weight Neonates (A) 482  
 Shah, Ajit K (coauthor) see Dimmitt, Dan C, 39  
 Shah, Prakash P (coauthor) see Smythe, Maureen A, 294  
 Shear, Neil H (coauthor) see Park, Hayley, 1249  
 Sherer, Jeffrey T (coauthor) see Baillie, G Mark, 233  
 Sherman, Richard A (coauthor) see Dahl, Naomi V, 1284  
 Shibakawa, Masahiko (coauthor) see Kusumoto, Masaki, 182  
 Shields, Catherine A (coauthor) see MacLaren, Robert, 1017  
 Simpson, Thomas A, Jr (coauthor) see Garrett, Clifford A, 1306  
 Silverblatt, Fredric J (coauthor) see Melbourne, Kathleen M, 1108  
 Silverstri, Rosalia C (author) Clozapine-Induced Seizures and EEG Abnormalities in Ambulatory Psychiatric Patients (RR) 1147  
 Simmons, Melissa M (author) Use and Abuse of Flunitrazepam (A) 117  
 Singh, Nina (coauthor) see Paterson, David L, 609  
 Sitar, Daniel S (coauthor) see Grymonpre, Ruby E, 749  
 Sitzman, Scott J (author) Treatment of Croup with Glucocorticoids (A) 973  
 Slater, William M (author) book review (B) 846  
 Slavik, Richard S (author) Trimethoprim/Sulfamethoxazole-Induced Tremor in a Patient with AIDS (CR) 189  
 Smith, Curtis L (author) Local Therapy for Cytomegalovirus Retinitis (A) 248  
 Smith, Jerry D (author) Possible Lansoprazole-Induced Eosinophilic Syndrome (CR) 196  
 Smith, Laura K (coauthor) see Michalets, Elizabeth Landrum, 761  
 Smith, Pamela S (author) Management of End-Stage Renal Disease in Children (A) 929  
 Smythe, Maureen A (author) book review (B) 721; (author) Pharmaceutical Care in Medical Progressive Care Patients (RR) 294  
 Song, Karen H (author) Botulinum Toxin Type A Injection for the Treatment of Frown Lines (A) 1365  
 Sorensen, Suellyn J (author) Successful Vancomycin Desensitization in a Patient with End-Stage Renal Disease and Anaphylactic Shock to Vancomycin (CR) 1020  
 Sossai, Paolo (author) Liver Injury with the Use of Ticlopidine (L) 1370  
 Souney, Paul F (coauthor) see Walters, J Ken, 478  
 Spallito, Anthony J (coauthor) see Dimmitt, Dan C, 39  
 Spiller, Sarah A (author) Low-Molecular-Weight Heparins for Acute Coronary Syndromes (A) 103; (author) Predictive Performance of Ten Equations for Estimating Creatinine Clearance in Cardiac Patients (RR) 1275  
 Spiteri, Terry L (coauthor) see Smythe, Maureen A, 294  
 Sramek, John J (coauthor) see Frackiewicz-Kozioł, Edyta J, 132  
 Stauffer, Virginia L (coauthor) see Steenberg, John A, 387  
 Stecker, Mark M (author) Paradoxical Response to Valproic Acid in a Patient with a Hypothalamic Hamartoma (CR) 1168  
 Steele, John W (coauthor) see Grymonpre, Ruby E, 743  
 Steenberg, John A (author) Potential Macrolide Interaction with Verapamil (L) 387  
 Stein, Daniel S (coauthor) see Griswold, Maria W, 475  
 Stein, Gary E (author) Single-Dose Treatment of Acute Cystitis with Fosfomycin Trometamol (A) 215  
 Steward, Caroline A (coauthor) see Dahl, Naomi V, 1284  
 Strayer, Andrew H (coauthor) see Freeman, Collin D, 1004  
 Streetman, Daniel S (coauthor) see Garey, Kevin W, 425; (coauthor) see Taylor, James R, 940  
 Stumbo, Phyllis J (coauthor) see Lewis, Dale P, 802, 947, 1087  
 Sundberg, Rubina (coauthor) see Zed, Peter J, 536  
 Sundin, David J (author) Toxicity Management in Patients Receiving Low-Dose Alendronate Therapy (A) 1344  
 Sunez, Lisa (coauthor) see Schlicht, John R, 715  
 Sutton, Brad M (coauthor) see Peak, Amy S, 504  
 Tabas, Gary H (coauthor) see Schlicht, John R, 715



Takeda, Kazuya (coauthor) see Kusumoto, Masaaki, 182  
 Takeyama, Masaharu (coauthor) see Morikawa, Norifumi, 269, 1008  
 Tallian, Kimberly B (author) Role of the Ketogenic Diet in Children with Intractable Seizures (A) 349  
 Tanaka, Kazuhiko (coauthor) see Kusumoto, Masaaki, 182  
 Tawil, Nadine (coauthor) see Martineau, Pierre, 588  
 Taylor, Charles T (coauthor) see Bradford, Greg S, 715  
 Taylor, James R (author) Medication Bezoars: A Literature Review and Report of a Case (A) 940  
 Tenero, David M (author) Effect of Ranitidine on the Pharmacokinetics of Orally Administered Eprosartan, an Angiotensin II Antagonist, in Healthy Male Volunteers (RR) 304  
 Terra, Steven G (author) Comment: Troglitazone Drug Interactions (L) 1111; (author) Opioid Antagonists in the Treatment of Pruritus from Cholestatic Liver Disease (A) 1228  
 Thompson, Gwendolyn H (author) Nicotine Replacement Therapy (A) 1067  
 Thompson, Robert L (author) Pleurodesis with Iodized Talc for Malignant Effusions Using Pigtail Catheters (RR) 739  
 Tkach, Carol L (author) Significance of a Tetracycline and Pepsin-Bismol Interaction in the Management of *Helicobacter pylori*-Induced Peptic Ulcer Disease (L) 387  
 Trakas, Kostas (coauthor) see Mittmann, Nicole, 1244  
 Trépanier, Eric F (author) Current Issues in Onychomycosis (A) 204  
 Trilli, Lauren E (coauthor) see Coast-Senior, Elizabeth A, 636  
 Trinkle, Randy (coauthor) see McLeod, Richard, 1110  
 Trippoli, Sabrina (coauthor) see Messori, Andrea, 716  
 Trissel, Lawrence A (author) Compatibility and Stability of Paclitaxel Combined with Doxorubicin Hydrochloride in Infusion Solutions (RR) 1013  
 Troutman, William G (coauthor) see Dodd, Melanie A, 887  
 Tsoo, Chang-Yong (coauthor) see Tallian, Kimberly B, 349  
 Tsourounis, Candy (coauthor) see Barclay, Teresa S, 574, 1371  
 Tsunoda, Shirley M (coauthor) see Terra, Steven G, 1228  
 Turco, Thomas F (author) Vancomycin Intermediate-Resistant *Staphylococcus aureus* (CR) 758  
 Ueno, Kazuyuki (coauthor) see Kusumoto, Masaaki, 182  
 Ulep, Sharon K (coauthor) see Devlin, John W, 869  
 Valencia, Mabel E (author) New Adverse Effect of Oxybutynin: "Night Terror" (L) 506  
 Van Dyke, Don C (coauthor) see Lewis, Dale P, 802, 947, 1087  
 Van Tassel, Eric D (coauthor) see Michalets, Elizabeth Landrum, 761  
 Vecchiotti, Gianluca (coauthor) see Wicki, Jacques, 892  
 Venkataramanan, Raman (author) Stability of Mycophenolate Mofetil as an Extemporaneous Suspension (RR) 755; (coauthor) see Murray, Michelle, 633  
 Vincent, Françoise H (coauthor) see Piquet, Catherine Y, 653  
 Voglino, Susan A (coauthor) see Bennett, Dean A Jr, 1201  
 Vondracek, Thomas G (author) Ranitidine Bismuth Citrate in the Treatment of *Helicobacter pylori* Infection and Duodenal Ulcer (A) 672  
 Wagner, Judy G (author) Beyond Benzodiazepines: Alternative Pharmacologic Agents for the Treatment of Insomnia (A) 680  
 Wagner, Mary L (coauthor) see Hempel, Alan G, 878; (coauthor) see Wagner, Judy G, 680  
 Wai, Amy O (author) Vancomycin-Induced Acute Interstitial Nephritis (CR) 1160  
 Walters, J Ken (author) The Use of Omeprazole in the Pediatric Population (A) 478  
 Ward, Kristina E (author) Dapsone-Induced Methemoglobinemia (CR) 549  
 Warty, Vijay S (coauthor) see Murray, Michelle, 633  
 Washam, Jeffrey B (coauthor) see Terra, Steven G, 1111  
 Watson, Dean D (coauthor) see Baltodano, Luis E, 1251  
 Wattanasuwan, Norrapol (coauthor) see Raggi, Paolo, 1141  
 Weart, C Wayne (coauthor) see Baillie, G Mark, 233; (coauthor) see Cerveny, John D, 896  
 Weber, Robert J (coauthor) see Schlacht, John R, 715  
 Weller, Richard (author) Penicillamine in the Etiology of Bullous Pemphigoid (VO) 1368

Wells, Philip S (coauthor) see Asch, Kathryn J, 765  
 Welty, Timothy E (coauthor) see Nahata, Milap C, 126  
 Westerholm, Barbro (coauthor) see Schmidt, Ingrid K, 27  
 White, Marion I (coauthor) see Weller, Richard, 1368  
 Wicki, Jacques (author) Rhabdomyolysis after Correction of Hyponatremia Due to Psychogenic Polydipsia Possibly Complicated by Clozapine (CR) 892  
 Willhite, Shannon L (author) Raloxifene Provides an Alternative for Osteoporosis Prevention (A) 834  
 Williams, J Robert (coauthor) see Turco, Thomas F, 758  
 Windisch, Paul A (author) Recombinant Human Growth Hormone for AIDS-Associated Wasting (A) 437  
 Wise, Steven L (coauthor) see Sorensen, Suellyn J, 1020  
 Woldvedt, Brent R (author) Possible Increased Anticoagulation Effect of Warfarin Induced by Azithromycin (L) 269  
 Wolfe, Thomas A (author) Comment: Once-Daily Aminoglycoside Dosing in Critically Ill Patients (L) 1109  
 Wolford, Eric T (coauthor) see Adcock, Kim G, 422  
 Wolin, Maurice J (coauthor) see Sundin, David J, 1344  
 Wong-Beringer, Annie (coauthor) see Beringer, Paul M, 176  
 Woodrum, Sharon T (author) Management of SSRI-Induced Sexual Dysfunction (A) 1209  
 Worland, Melinda A (author) Intraperitoneal Thrombolytic Therapy for Peritoneal Dialysis-Associated Peritonitis (A) 1216  
 Wright, James M (coauthor) see Etminan, Mahyar, 1193  
 Wright, Letitia J (author) book review (B) 508  
 Xu, Quanyun A (coauthor) see Trissel, Lawrence A, 1013  
 Yau, Jonathan C (coauthor) see Thompson, Robert L, 739  
 Yee, Helen S (author) Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias (A) 1030  
 Yildiz, Bulent O (author) Alendazole-Induced Amegakaryocytic Thrombocytopenic Purpura (L) 842  
 Yollis, Jennifer C (coauthor) see Alao, Adeola O, 889  
 Yoshida, Eric M (coauthor) see Carr, Roxane R, 45  
 Young, Tammy M (coauthor) see Knoll, Karen R, 1299  
 Zahn, Ralf W (coauthor) see Nobile, Alessandro, 120  
 Zarembo, Cameron D (author) Comment: Could Acetaminophen have Played a Role in a Possible Azithromycin-Warfarin Interaction? (L) 844  
 Zarowitz, Barbara J (coauthor) see Devlin, John W, 869; (coauthor) see Joy, Melanie S, 362  
 Zed, Peter J (author) Cost-Effectiveness Analysis of Abciximab: A Canadian Hospital Perspective (RR) 536  
 Zimmermann, Anthony E (coauthor) see Walters, J Ken, 478  
 Zlotnik, Vladislav (coauthor) see Bennett, Dean A Jr, 1201  
 Zograf, George (author) An Essential Societal Role (A) 471  
 Zuckerman, Sheila (coauthor) see Venkataramanan, Raman, 755

ology, Third Edition, 623, 631, ibc-J/A, ibc-Sept, ifc-Oct, ibc-Nov, ifc-Dec; **Pharmacy Technician Education & Training, 1998 Directory**, 553, 727, 768, 982; **Principles of Pharmacoeconomics, Second Edition**, ibc-Jan, 507, ibc-May, 730, 994, 1128, 1264, 1383; **The Annals of Pharmacotherapy**, PharmaCE, 145, 273, 395, 514, 614, 728, 855, 993, 1120, 1258, 1384; bound volumes, 119, 181, 394, 421, 542, 711, 817, 992; subscription, 8, 164, 283, 516, 522, 617, 632, 723, 736, 866, 975, 1003, 1113, 1134, 1259, 1271; **Therapeutics in the Elderly, Second Edition**, 12  
**Personnel Placement, Canada**, University of Alberta, 1265; **Department of Veterans Affairs**, 149, 1377; **Florida**, University of Florida, 995; **Lebanon**, Lebanese American University, 396; **Nebraska**, University of Nebraska Medical Center, 856; **New Jersey**, Morristown Memorial Hospital, 515, 1125; **North Carolina**, Pitt County Memorial Hospital, 995; **Ohio**, Harvey Whitney Books Company, 622, 729, 862, 1000, 1126; **Pennsylvania**, Centocor, 1125, Wilkes University, 856; **Singapore**, National University of Singapore, 1125, 1379; **South Dakota**, Rapid City Regional Hospital, 278; **Texas**, Alcon Laboratories, Inc, 622; **West Virginia**, Robert C Byrd Health Sciences Center, West Virginia University, 150, 278, 1378  
**Pfizer, Inc**, Zolet, ibc-Feb, ibc-Apr, ibc-June, ibc-Oct, ibc-Dec  
**Wyeth-Ayerst Laboratories**, Cordarone, 147, 389, 599, 853, ifc-Sept, ifc-Nov, Duract, ifc-May, ifc-J/A; Suprax, 403; Ziac, ifc-Feb, ifc-Apr, ifc-June

## INDEX ABBREVIATIONS

A: Article  
 CR: Case Report  
 E: Editorial  
 ibc: inside back cover  
 ifc: inside front cover  
 IR: International Report  
 L: Letter  
 NC: News and Comments  
 O: Opinion  
 obc: outside back cover  
 RR: Research Report  
 S: Symposium Proceedings  
 VO: Visual Observations

## ADVERTISER INDEX

American Society of Health-System Pharmacists, AHFS Drug Information, 152, 1257  
 Bayer Corporation, Cipro, ibc-Jan, ibc-Mar, obc-May, obc-J/A, obc-Sept, obc-Nov  
 Board of Pharmaceutical Specialties, BPS Certified Specialist, 621  
 Boehringer Ingelheim Pharmaceuticals, Inc, Flomax, 13, ifc-Mar, 523, 737, 867, 1139  
 Fujisawa USA, Inc, AmBisome, 1, 165, 289  
 Harvey Whitney Books Company, Books and Journals for Pharmacy and Pharmacotherapy, 9, 159, 286, 501, 604, 718, 857, 983, 1117, 1135, 1272; CA/CTF, 156, 1124, 1254, 1394; Certification Review for Pharmacy Technicians, Fourth Edition, 1247; Pediatric Drug Formulations, Third Edition, 151, 510, 608, 997, 1138, 1389; Pharmacoeconomic

Statement of ownership, management, and monthly circulation (11 issues, \$219.00 annually) of *The Annals of Pharmacotherapy*, publication no. 1060-0280. Owner, Harvey Whitney Books Company, Publisher, editor, and managing editor: Harvey AK Whitney Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, PO Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies of each issue from October 97 to October 98 and no. of copies of October 98 issue: A. total no. copies printed (net press run) 5650, 5700; B. paid and/or requested circulation (1) sales through dealers and carriers, street vendors, and counter sales 0, 0; (2) paid or requested mail subscriptions 4835, 5000; C. total paid and/or requested circulation 4835, 5000; D. free distribution by mail 365, 365; E. free distribution outside the mail 0, 0; F. total free distribution 365, 365; G. total distribution 5200, 5365; H. copies not distributed (1) office use, leftovers, spoiled 450, 335; I. total 5650, 5700. No. of issues published annually: 11. Date of filing 1 October 1998. Signed: Harvey AK Whitney Jr, Publisher.



